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ABSTRACT OF DISSERTATION

ZHX2 REGULATION OF LIPID METABOLISM AND THE BALANCE BETWEEN
CARDIOVASCULAR AND HEPATIC HEALTH
The growing obesity epidemic in America carries with it numerous health
risks, including diabetes, increased serum lipid levels, and excess fat
accumulation in the liver. If these conditions persist or become exacerbated, they
may lead to the development of cardiovascular disease, the current leading
cause of death among Americans, or to nonalcoholic fatty liver disease (NAFLD)
which can progress to hepatocellular carcinoma (HCC), one of the deadliest
forms of cancer. Better understanding of the genes involved in these diseases
can lead to improved identification of at-risk individuals and treatment strategies.
Our lab previously identified zinc fingers and homeoboxes 2 (Zhx2) as a
regulator of hepatic gene expression. The BALB/cJ mouse strain has a
hypomorphic mutation in the Zhx2 gene, causing a 95% reduction in Zhx2 protein
expression. The near ablation of Zhx2 in BALB/cJ mice confers protection from
cardiovascular disease when fed a high fat diet, yet these mice show increased
hepatic lipid accumulation and liver damage. Microarray data indicates Zhx2 may
be involved in the regulation of numerous genes involved in lipid metabolism.
Recent GWAS studies indicate ZHX2 may contribute to the risk of cardiovascular
disease and liver damage in humans as well.
In this dissertation, I characterize the role of Zhx2 expression in the liver
and how it affects the risk of both cardiovascular disease and liver damage. I
generated liver-specific Zhx2 knockout mice and confirmed Zhx2 regulates
several novel targets that could contribute to the fatty liver phenotype seen in
BALB/cJ mice. Further studies revealed that hepatic Zhx2 expression is
necessary for proper sex-specific expression of several Cyptochrome P450
(CYP) genes and could contribute to gender differences in disease susceptibility.
Lastly, I performed studies into the functional role of the Zhx2 target gene Elovl3.
A mouse model of HCC revealed that Elovl3 is completely repressed in HCC
tumors. Cell viability and cell cycle assays indicate that Elovl3 expression slows
cell proliferation and may be important for proper cell cycle checkpoints.
Together, these data indicate that Zhx2 and/or its targets could be clinically

relevant in the detection, prevention, or treatment of cardiovascular disease, fatty
liver, and HCC.
KEYWORDS: Zinc fingers and homeoboxes 2, gene regulation, lipid metabolism,
cancer, cardiovascular disease
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Chapter One
Introduction
The liver is a key metabolic organ in mammals and its proper functioning
is necessary to maintain health. The liver is responsible for the metabolism of
macronutrients from dietary intake, including maintaining serum glucose balance,
synthesizing non-essential amino acids and proteins, regulating lipid utilization
and storage, and transporting these molecules through the body (Figure 1).
Additionally, the liver is main site for synthesis of cholesterol and steroid
hormones, bile acids, and serum transport proteins (i.e. albumin). The diverse
functions of the liver continue with its role in detoxification of xenobiotic
compounds and the elimination of harmful or excessive byproducts (ammonia,
cholesterol) from the body. Most of the described metabolic functions are
performed by hepatocytes, the predominant cell type in the liver. Hepatocytes
comprise 80% of the liver mass, but only about 60% of the actual cells within the
liver. Other liver cell types include Kuppfer cell (resident macrophages) natural
killer (NK) cells (also known as Pit cells), as well as hepatic stellate cells, which
serve as Vitamin A stores in quiescent states but produce collagen upon liver
damage and can lead to fibrosis [1]. The remaining liver cells are sinusoidal and
biliary endothelial cells which form a cell barrier between hepatocytes and the
blood and bile ducts, respectively [2]. As hepatocytes are the primary
contributors to metabolic functions of the liver, they will be the focus of this
dissertation.
Liver Lipid Metabolism
Hepatocytes in the liver are the main site of multiple aspects of lipid
metabolism and homeostasis. Under fasting conditions, blood glucose levels are
low which results in the pancreatic release of the peptide hormone glucagon.
Glucagon binds to receptors expressed on hepatocytes to activate
1

glycogenolysis, the cleavage of glucose molecules from the stored form
glycogen. If fasting is prolonged and glycogen stores are depleted, glucagon
activates hormone sensitive lipase in adipose tissue to hydrolyze fatty acids for
an energy source for most tissues. Fats released from adipose depots undergo
beta-oxidation in mitochondria to produce two-carbon acetyl-CoA units that are
substrates for the Citric Acid Cycle and ATP synthesis. Fatty acids can also be
transported to the liver where they are converted to glucose through
gluconeogenesis, and during extreme fasting, they are converted to ketone
bodies as an alternate energy source.
In the fed state, short chain fatty acids (<C12), carbohydrates, and
proteins are transported from the small intestine directly to the liver through the
hepatic portal vein. Longer chain fatty acids, dietary cholesterol, and the fat
soluble vitamins A, D, E, and K are packaged into triglyceride-rich chylomicrons
that are transported through circulating blood to peripheral tissues. Interaction
between apoCII in the chylomicron membrane and the cell surface enzyme
lipoprotein lipase (Lpl) in peripheral tissues activates Lpl to hydrolyze dietary
triglycerides into monoglycerol and two free fatty acids that can be transported
into the cell. Chylomicron remnants or chylomicrons not utilized by peripheral
tissues are transported through systemic circulation to the liver, where apoE
binds hepatic receptors to deliver cholesterol, fat-soluble vitamins, and fatty acids
for processing by hepatocytes. When dietary intake of carbohydrates and/or
lipids is in excess of immediate physiologic need, hepatocytes convert them to
triglycerides to be stored mostly in adipose tissue, but also to a lesser degree in
the liver. Hepatocytes package triglycerides along with cholesterol in VLDL
particles which are exported into the circulation, and again taken up by peripheral
tissues by Lpl activation and hydrolysis. After triglycerides are deposited to other
cells, the remaining cholesterol-containing particles are considered LDL and
continue to circulate and transport cholesterol to peripheral tissues and back to
the liver through receptor-mediated endocytosis. Hepatocytes synthesize apoAI
and apoAII which are incorporated into the membrane of nascent HDL
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lipoproteins that facilitate cholesterol uptake from peripheral tissues and transport
it back to the liver, where it may be excreted as bile.
Hepatocytes respond to increased glucose availability and insulin
signaling through coordinated transcriptional regulation of genes to increase the
synthesis of fatty acids and triglycerides. One key event is insulin signaling to
activate SREBP1c-mediated induction of lipogenesis in the liver, with resulting
fatty acids and triglycerides then transported in VLDL particles to peripheral
tissues or adipose for storage [3, 4]. The cellular sterol content regulates the
activity of SREBP1a and SREBP2 to induce cholesterol biosynthesis [4].
Cholesterol is an essential cellular component and is incorporated into
membranes with roles in signal transduction and transport of molecules.
Cholesterol is the precursor to bile acids, which are required for the
emulsification and absorption of lipids in the digestive tract. Cholesterol is also
the precursor to steroid hormones, including the sex hormones testosterone,
estrogen and progesterone [5]. Steroid hormone synthesis involves metabolism
by the cytochrome P450 (CYP) family of enzymes. CYPs function as
monooxygenases that are involved in both the synthesis and degradation of
various compounds, including lipid products and steroids, Vitamin D, bilirubin,
ethanol, drugs, and toxic byproducts from nutrient metabolism [6]. There are a
large number of CYP enzymes, as each subgroup operates in response to
specific stimuli. Due to the metabolism of sex hormones and other substances,
many CYPs are expressed in a gender-specific manner. The regulation of
sexually dimorphic CYP expression appears to be in response to growth
hormone signaling [7, 8].
Disorders of lipid metabolism and health implications
Disruptions in the synthesis and storage of triglycerides can manifest in a
variety of detrimental health concerns. A main cause of disregulated lipid
homeostasis is diet induced obesity, which has quickly risen to epidemic
proportions in the U.S., with current estimates of 34.9% of adults (78.6 million)
classifying as obese [9]. The excess energy supply characteristic of obesity is
3

stored as triglycerides in adipose tissue, which can also accumulate in the liver
[10]. Increased hepatic lipid accumulation has been associated with insulin
resistance and Type 2 Diabetes, hyperlipidemia, atherosclerosis,
hepatosteatosis, non-alcoholic fatty liver disease (NAFLD), and hepatocellular
carcinoma (HCC) [10, 11].
NAFLD is a term used to describe the excessive presence of lipids in the
liver that is not a result of alcohol consumption. NAFLD has several categories of
manifestations with advancing disease states. Hepatic steatosis (fatty liver) is
characterized as lipid droplet accumulation in hepatocytes and is the result of an
imbalance in the triglyceride synthesis, transport, or utilization pathways [11].
Steatosis is a reversible condition and can be alleviated with dietary and activity
modifications [12]. Unfortunately, steatosis is highly prevalent in people with
obesity, type 2 diabetes, and metabolic syndrome, and often progresses to a
more severe condition, hepatitis [13-15]. Hepatitis is an inflammatory condition
marked by infiltration of immune cells and increased necrosis and apoptosis of
damaged cells [15]. It has been strongly implicated that the inflammation
associated with hepatitis can cause or exacerbate insulin resistance [11, 14, 16].
Hepatic inflammation can interfere with normal insulin response and glucose
utilization, which then results in a metabolic switch to induce lipolysis, releasing
triglycerides into the blood and causing hyperlipidemia. Dyslipidemia, elevated
serum glucose, and obesity are key features of metabolic syndrome, which is a
key risk factor in developing cardiovascular disease [17, 18]. There is growing
evidence that NAFLD increases atherosclerotic plaque formation and elevates
incidence of cardiovascular disease [13, 19, 20]. It is difficult to determine if
NAFLD is an independent cause of atherosclerosis because it usually occurs in
conjunction with other risk factors. Cardiovascular disease is the leading cause of
death among Americans, and the number of people at risk is expected to
continue to increase along with the rising obesity rate [21].
In addition to the cardiovascular implications of NAFLD, the inflammation
and increasing damage to hepatocytes can result in fibrosis, the development of
4

scarring that interferes with normal liver function, and cirrhosis. Hepatic stellate
cells become activated in response to increasing hepatocyte death. Stellate cells
attempt to repair damaged tissue by expanding collagen fibers and extracellular
matrix proteins around the injury site [15]. Prolonged damage increases the
amount of collagen produced and results in cirrhosis. Cirrhosis is considered
end-stage liver disease and results in liver failure and death [22]. Between 5-30%
of people with cirrhosis will progress to HCC, depending on the disease severity
at diagnosis and other risk factors [23]. HCC is the fifth most common cancer and
is the third leading cause of cancer deaths worldwide. The most common causes
of HCC are viral infections (hepatitis B and C) and alcohol abuse [15]. Patients
with these risk factors can undergo serum screening for elevated alphafetoprotein (AFP) and ultrasound imaging for HCC tumor detection, which are
currently the best methods of identifying HCC. These methods are not highly
specific or accurate since serum AFP can be elevated in response to any type of
liver damage, and many people do not present with the traditional risk factors for
HCC. In recent years, metabolic syndrome and associated NAFLD have become
increasingly linked to HCC. HCC has a high mortality rate and very poor survival
prognosis in part because there are few reliable diagnostic markers for HCC,
which is an alarming realization when paired with a huge potential increase in
people at risk due to obesity and metabolic syndrome. HCC is projected to be the
third leading cause of cancer deaths in the United States by 2030 [24]. A better
understanding of early events in the development of HCC and better detection
methods is critical to preventing this anticipated surge in HCC related deaths.

Zinc Fingers and Homeoboxes 2 (Zhx2)
AFP was the first diagnosed oncofetal gene in that it is normally
expressed during fetal life, silenced at birth, and reactivated in cancer [25].
Serum AFP levels is a widely used diagnostic marker to detect liver damage and
possible HCC, so understanding its expression is of clinical interest. A screen of
various mouse strains revealed very low AFP levels in adult serum [26].
However, the one exception was the BALB/cJ substrain, with serum AFP levels
5

roughly 20-fold higher than other mouse strains (Figure 2). The persistent AFP
expression in BALB/cJ mice was characterized as a monogenic trait and mapped
to mouse chromosome 15 [27]. Additional studies indicated that elevated serum
AFP levels correlated with increased hepatic AFP mRNA levels, suggesting that
difference was occurring at the level of gene regulation [26]. A molecular screen
for other genes expressed similarly to AFP (high in fetal liver, silenced at birth,
persistent expression in adult BALB/cJ liver) identified H19 as another Zhx2
target [28]. Our lab found that Glypican 3 (Gpc3) is silenced in the perinatal liver
but expressed at higher levels in BALB/cJ liver [29], similarly to AFP and H19.
Using positional cloning, our lab identified a mutation in the BALB/cJ Zhx2 allele
as being responsible for the persistent AFP and H19 expression in the adult liver
of these mice [30]. For confirmation, overexpression of a liver-specific Zhx2
transgene in BALB/cJ mice resulted in normal AFP and H19 silencing after birth
[30] (Figure 3). The mutation in BALB/cJ Zhx2 allele is due to a Mouse
Endogenous Retroviral (MERV) insertion element within the first Zhx2 intron that
dramatically reduces, but does not eliminate, Zhx2 expression [30, 31]. Thus, the
Zhx2 mutation in BALB/cJ mice is hypomorphic, resulting in Zhx2 mRNA levels
that are roughly 5% of that found in strains with a wild-type Zhx2 allele. These
combined data suggest that Zhx2 functions to repress target genes in the
perinatal liver, and the reduction in Zhx2 levels in BALB/cJ livers results in
persistent expression of these genes.
Zhx2 is the member of a small family of highly conserved vertebratespecific genes (Zhx1, Zhx2 and Zhx3). Each Zhx protein contains two aminoterminal C2H2 zinc finger domains, typically associated with DNA, RNA, and
protein interactions, and four to five carboxy-terminal DNA-binding
homeodomains, suggesting that these proteins function as transcriptional
regulators [32]. Early studies indicate that ZHX proteins can homodimerize and
heterodimerize with each other, and luciferase assays suggest that ZHX proteins
function as transcriptional repressors [32, 33]. Chromatin immunoprecipitation
(ChIP) and luciferase reporter assays indicate that ZHX2 binds to and regulates
the human AFP and Gpc3 promoters [34]. Taken together, these data are
6

consistent with our model of Zhx2 acting to repress AFP and Gpc3 expression in
the adult liver. Further, ChIP analysis in human HCC cell lines indicate that ZHX2
binds to the promoter regions of CCNA2 and CCNE1, the genes coding for
Cyclins A and E, respectively, and inhibited their transcription [35]. However,
other data suggests Zhx2 may regulate target gene expression at the
posttranscriptional level (Martha Peterson, unpublished data, [36]). Additionally,
as described in this dissertation, we have recently identified several novel Zhx2
targets, including Elovl3, Cyp2a4, and MUPs, that are regulated by Zhx2. These
data indicate that Zhx2 is involved in both gene activation and repression.
Zhx2 targets in HCC and other diseases
The Zhx2 target AFP serves as a model for examining gene expression in
fetal development and disease. AFP is expressed at very high levels in the fetal
liver, repressed over 1000-fold shortly after birth, and becomes reactivated in
liver damage [25, 37]. AFP is a serum transport protein that circulates lipids,
steroids, and other substances through the body. Although it is commonly used
as a diagnostic marker for liver damage and HCC, the functional relevance of its
increased expression in liver disease is not clear. In humans, hereditary
persistence of AFP (HPAFP) is considered a benign condition with no known
health risks [38] Known cases of HPAFP have indicated a mutation in the
hepatocyte nuclear factor-1 (HNF1) binding site in the AFP promoter results in
the elevated AFP expression [39, 40]. Although the basis for persistent AFP
expression in adult BALB/cJ mice is different than HPAFP in humans, they
similarly do not appear to have any adverse consequences associated with
increase serum AFP levels.
Since AFP is frequently reactivated in HCC, there is interest in whether
other Zhx2 targets and Zhx2 itself are disregulated in HCC. Gpc3 has a similar
expression pattern to AFP in that it is expressed in the fetal liver, repressed at
birth, and remains silent in normal adult tissue [41]. Gpc3 is a heparin sulfate
proteoglycan present on the cell surface and linked to the membrane by
phosphatidylinositol [42]. Proteins in this category are associated with cell-cell
7

interactions and formation of extracellular matrix, and may integrate signals for
cell growth and division. Humans with loss of function Gpc3 mutations suffer from
Simpson-Golabi-Behmel Syndrome (SGBS), characterized by overgrowth in both
prenatal and postnatal development, multiple body dysmorphisms, and frequent
death in infancy [43]. Gpc3 knockout mice display many of these maladies, but
studies in the mice have not elucidated the mechanism that causes SGBS [44].
Gpc3 is silenced in normal adult tissues but becomes elevated in HCC, making it
another candidate HCC diagnostic marker. In fact, some studies suggest Gpc3 is
more specific for HCC than AFP and could be used for more accurate diagnosis
[34]. Elevated serum Gpc3 is associated with poor prognosis in HCC patients
[45] and increased Gpcs3 detected by IHC has over 95% predictive rate of
pediatric hepatoblastoma [46]. Gpc3 may increase the metastatic properties of
cells through ERK signaling [47]. Antibodies targeting Gpc3 inhibit Wnt signaling
and reduce tumor xenografts in nude mice [48], so there is potential for HCC
therapeutic treatment by regulating Gpc3.
H19 was the second Zhx2 target to be identified. H19 is a long non-coding
RNA and serves as a model of parent-of-origin genomic imprinting [49]. The H19
transcript is processed into microRNA (miR) [50], and may also interact with
other miRs and thus contributes to gene regulation [51]. H19 knockout mice
appear to develop normally, yet overexpression of H19 in zygotes results in
perinatal death [52]. The role of H19 in tumorigenesis has yet to be elucidated.
Studies have reported increased H19 expression in pancreatic, ovarian, and
bladder cancers [53-55]. Additional studies suggest that H19 is necessary for
HCC tumor growth [56], and targeted interference of H19 inhibits cell proliferation
and induces apoptosis [57]. In contrast, H19 has also been identified as a tumor
suppressor in colorectal cancer and in HCC [58]. Based on these conflicting data,
further analysis of the role of H19 in cancer is warranted. In addition to its
involvement in cancer, polymorphisms in H19 has been associated with
increased risk of coronary artery disease (CAD) in Chinese men [59]. The impact
of the polymorphism is unknown, but altered H19 expression increased the risk
and severity of CAD in the study subjects.
8

Lipoprotein lipase (Lpl) is expressed at high levels in the fetal liver,
silenced at birth, continues to be expressed at elevated levels in adult BALB/cJ
liver, and silenced in BALB/cJ mice expressing a liver-specific Zhx2 transgene
(H. Ren, unpublished). This suggests that Lpl is also a target of Zhx2. Increased
Lpl expression has been observed in cases of HCC as well as cervical squamous
cell carcinoma, chronic lymphocytic leukemia, and non-small cell lung cancer
[60-62]. Lpl facilitates the uptake of fatty acids into cells for energy production,
which is necessary for the high metabolic requirements of tumorigenic cells [63].
Although its expression is altered in cancer, normal Lpl expression is necessary
for fetal development and cardiovascular health in mature organisms. Lpl
knockout mice suffer from severe hyperlipidemia and die shortly after birth due to
blood saturation of chylomicrons and lack of energy in peripheral tissues [64].
Partial deletion mutations in human LPL are associated with elevated serum
lipoproteins [65, 66]. Lpl overexpression in otherwise healthy animal models
alters lipid metabolism, results in increased atherosclerosis and skeletal muscle
damage due to lipotoxicity [67, 68], and may contribute to insulin resistance [69].
In mouse models of diabetes, increased transgenic Lpl expression has a
protective effect and has been shown to reduce diabetic hyperlipidemia and
lessen atherosclerotic lesions [70]. The cardioprotective effect may depend on
tissue-specific expression, as reduced Lpl in vascular tissue is associated with
less lipoprotein infiltration [71].

The disregulation of many Zhx2 targets in HCC leads to question if Zhx2
expression is also altered in liver cancer. Current data regarding Zhx2 expression
in HCC tumors are conflicting. A study utilizing sequence screening of tumor and
adjacent non-tumor tissue reported that CpG islands in the Zhx2 promoter were
hypermethylated in HCC, resulting in reduced Zhx2 expression in tumors [72]. In
contrast, another study analyzing tissue samples by immunohistochemistry (IHC)
noted that Zhx2 protein was expressed only in HCC samples compared to
cirrhotic liver, cholangitis samples, and normal adjacent tissue [73]. This second
study also indicated that increased Zhx2 was associated with more advanced
9

stages of HCC. Dr. Chunhong Ma and our collaborators at Shandong University,
China have found that ZHX2 overexpression reduced proliferation of HCC cells
as well as reduced the growth of tumor xenografts in nude mice [35]. Further,
they showed that the Zhx2 proteins were primarily in the nucleus in non-tumor
liver tissue, but localized to the cytoplasm in HCC samples [35]. This data
suggests that ZHX2 is excluded from the nucleus in HCC, effectively blocking its
ability to control expression of target genes. More recently, our collaborators
published data showing again reduced nuclear ZHX2 localization in HCC tumors
and a resulting increase in Gpc3 expression in human patient samples [34]. In
tumor samples from a mouse model of HCC, my analysis indicates increased
mRNA levels of AFP, Gpc3 and Lpl in tumors compared to control liver samples,
but no difference in total Zhx2 mRNA expression in normal and HCC samples
(Figure 4). My analysis of mouse HCC samples indicates that Zhx2 accumulates
in the cytoplasm and is excluded from the nucleus, consistent with published
findings. The nuclear exclusion seen in these samples would likely cause the
disregulation of target genes without necessarily altering the total Zhx2 mRNA or
protein levels. The mechanism causing the altered Zhx2 localization and
subsequent disregulation of target gene expression will provide great insight into
the progression of liver damage and HCC, and may identify new therapeutic
targets.
Zhx2 has also been implicated in the regulation of lipid metabolism genes
and cardiovascular disease risk. Serum lipid analysis performed on various
mouse strains found that on a high fat diet (HFD), BALB/cJ mice have reduced
serum lipid levels and fewer atherosclerotic plaques than other strains.
Quantitative trait locus (QTL) mapping identified this trait, known as
Hyperlipidemia2 (Hylip2), to a region on mouse chromosome 15 [74]. The Hylip2
phenotype results in hypertriglyceridemia due to reduced clearance of serum
triglycerides. The BALB/cJ Hyplip2 allele confers cardiovascular protection by
increased triglyceride clearance and lower circulating lipid levels, resulting in
fewer atherosclerotic lesions. In collaboration with the lab of Jake Lusis (UCLA),
we identified Zhx2 as the gene responsible for the Hylip2 phenotype [75].
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BALB/cJ mice expressing a liver-specific Zhx2 transgene exhibited significantly
higher plasma cholesterol and triglycerides and increased atherosclerotic
plaques compared to non-transgenic BALB/cJ littermates. Consistent with this
mouse data, ZHX2 has been identified in two human GWAS studies with
interactions in cardiovascular disease. GWAS analysis of over 31,000 patients in
the CHARGE consortium identified single nucleotide polymorphisms (SNPs) in
ZHX2 as the strongest predictive factor of lower carotid intima media thickness
(cIMT), a subclinical marker of atherosclerosis [76]. A GWAS study analyzing
data gathered on black and white males in the Bogalusa Heart Study found that a
particular ZHX2 SNP was strongly associated with cIMT in white males [77]. It is
not clear how the SNPs evaluated in the study affect the expression or function
of ZHX2 in humans, but these data indicate ZHX2 has a role in the risk of
developing cardiovascular disease in humans. The significance of Zhx2
involvement in serum lipid levels and cardiovascular disease risk is a new
avenue of investigation for our lab. The Lusis lab performed microarray analysis
in congenic mice expressing wild-type or the mutated BALB/cJ Zhx2 alleles. This
analysis identified over 1000 genes that showed differences in expression in the
presence or absence of Zhx2 and are therefore potential new targets of Zhx2.
My dissertation explores the effects of Zhx2 on the regulation of lipid
metabolism gene expression and resulting disease risk. Many of these studies
have utilized a novel mouse model I developed that utilized mice with a floxed
allele of Zhx2 in the BL/6 background; by crossing these mice with Albumin-Cre
transgenic mice, I have been able to delete Zhx2 specifically in hepatocytes. I
have identified several novel Zhx2 targets and further developed the mechanism
by which hepatic Zhx2 deletion increases hepatic lipid accumulation, resulting in
lower serum triglycerides and lower risk of cardiovascular disease. I have
identified the cytochrome P450 enzyme Cyp2a4 as a Zhx2 target, and
discovered that Zhx2 regulates sexually dimorphic CYP gene expression in the
adult liver. Additionally, I have characterized the regulation and function of the
Zhx2 target Elongation of very long chain fatty acids-like 3 (Elovl3) in cell cycle
regulation and HCC progression.
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Figure 1. Overview of lipid metabolism in the liver. The liver is the main
processing site of nutrient metabolites. The liver synthesizes numerous
Cytochrome P450 (Cyp) enzymes which synthesize cholesterol and bile acids, as
well as break down drugs, toxins, and other substances to be removed from the
body. Bile secretion into the intestine is necessary for the absorption of dietary
fats that are packaged into chylomicron particles. Lipoprotein lipase (Lpl) on the
surface of peripheral tissues hydrolyzes triglycerides from chylomicrons for
uptake into cells. Unused remnants travel back to the liver for processing.
Cholesterol is exported from the liver in VLDL particles for delivery of substances
to peripheral tissues, and unused particles are reabsorbed by the liver. In cases
of excess dietary intake, fat can accumulate in the liver, causing non-alcoholic
fatty liver disease (NAFLD). Continued damage resulting in inflammation and
macrophage infiltration is characterized as non-alcoholic steatohepatitis (NASH).
Prolonged damage to the liver increases the risk of hepatocellular carcinoma
(HCC).
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Figure 2. Postnatal AFP repression in inbred mouse strains. RNA was
isolated from mouse livers at embryonic day 19 and periodically from birth to day
28. Mice have high AFP expression during fetal development which is repressed
after birth. C3H and B6 mice have rapid and dramatic repression of AFP
expression. BALB/cJ mice have delayed onset of repression that is incomplete
at day 28. BALB/cJ mice continue to express AFP 10 to 20-fold higher than other
mouse strains. Copyright 1982 Molecular and Cellular Biology.
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Figure 3. Hepatic Zhx2 transgene expression restores AFP repression.
Mouse liver RNA amplified by RT-PCR to detect Zhx2, AFP, and Zhx2 transgene
expression. BALB/c mice with wildtype Zhx2 expression (Lane 1) have postnatal
AFP repression. BALB/cJ mice (Lanes 2-3) have greatly diminished Zhx2
expression and persistent AFP expression. BALB/cJ mice with liver-specific
Zhx2 expression (Lanes 4-5) have elevated Zhx2 and restoration of AFP
repression. These data confirm Zhx2 represses AFP in the mouse liver. L.
Morford, unpublished data.
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Figure 4. Zhx2 targets, but not Zhx2, are overexpressed in HCC tumors.
Male C3H-B6 F1 offspring were injected with PBS (n=5) or DEN (n=16) to initiate
liver tumor development in a mouse model of HCC. At 36 weeks post-injection,
liver and tumor samples were collected and analyzed by qPCR for expression of
Zhx2 (A), and its targets AFP (B), Gpc3 (C), and Lpl (D). AFP, Gpc3, and Lpl
have increased mRNA expression in HCC tumors, but Zhx2 expression does not
change. Values are normalized expression shown as fold change to controls. *
p<0.05, **p<0.01.
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Chapter 2
Materials and Methods
Mice
All mice were housed in the University of Kentucky Division of Laboratory Animal
Research (DLAR) facility and kept according to Institutional Animal Care and Use
Committee (IACUC) approved protocols. All mice had ad libitum access to food
and water and were maintained on a 12/12 hour light/dark cycle.
Generation of hepatocyte-specific Zhx2 knockout (Zhx2∆hep) mice:
Breeding pairs of C57Bl/6 mice with a Zhx2 floxed allele (Zhx2fl) were purchased
from the Knockout Mouse Project Repository at the University of CaliforniaDavis. In these mice, exon 3 has been flanked by loxP sites. Since the entire
Zhx2 coding region is found on exon 3, deletion of this exon results in the loss of
the entire Zhx2 protein. These mice were crossed with C57/Bl6 mice expressing
cre recombinase driven by the liver-specific Albumin promoter (Alb-Cre) (Jackson
Labs). Mice were bred to achieve homozygous floxed Zhx2 alleles with Alb-Cre
expression (Zhx2∆hep), or without Alb-Cre (Zhx2f/f) serving as littermate controls.
Mice were maintained under normal conditions until 4-8 weeks old, then
euthanized by CO2 asphyxiation for tissue harvest.
Genotyping:
At approximately 10-days of age, each mouse pup was given an ear punch for
identification and the tissue was collected. DNA was extracted by incubation in
lysis buffer (100mM Tris-HCl pH 8.5, 5mM EDTA, 200mM NaCl) with 2.5 units
proteinase K (Sigma) followed by isopropanol precipitation and washing with
95% ethanol. The DNA pellet was resuspended in water, then genotyped by PCR
amplification using the appropriate primers (Table 1) with ThermoStart Master
Mix according to manufacturer’s protocol (ThermoScientific). Samples were
analyzed by gel electrophoresis and visualized by a UV lightbox.
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Murine model of atherosclerosis with hepatocyte specific Zhx2 knockout mice:
A breeding pair of LDLr-/- mice were purchased from Jackson Laboratory. After
two weeks of acclimation, LDLr-/- mice were bred to Zhx2f/f and Zhx2∆hep mice.
Offspring were genotyped and crossbred to obtain homozygous LDLr-/- and
Zhx2f/f with and without Alb-Cre expression. LDLr-/-, Zhx2∆hep and control LDLr-/-,
Zhx2f/f littermates were weaned onto a high fat, high cholesterol diet (TD.94059,
Harlan Teklad; Appendix A) at 21 days old and were maintained on this diet for
18 weeks. Mice were monitored for weight gain every week, and serum
collections were obtained every 4 weeks throughout the study.

Serum Collection:
Starting at the second week on the HFD study (mouse age 5 weeks old) and
repeated every four weeks, serum collections were obtained by submandibular
bleeding. Mice were fasted starting at 8:00am for five hours but had access to
water. Mice were manually restrained and punched with a lancet
(Goldenrod/Medinet) to penetrate the submandibular vein in the cheek. Blood
was collected in a serum separator tube (~20-100ul blood per collection,
depending on age of mouse) and incubated at room temperature for at least 30
minutes before centrifugation at 13000 xg rcf for 1 minute. Serum was aspirated
by pipetting and transferred to a 1.5ml Eppendorf tube and stored at -80°C.

Euthanasia and Tissue Collection:
Mice were maintained on HFD for 18 weeks with weekly weight measurements
and monthly serum collections. After the 18th week, mice were fasted beginning
at 8:00am for five hours. Mice were weighed and administered Tribromoethanol
(Avertin) by intraperitoneal injection (250 mg/Kg body weight) and monitored for
non-responsiveness to sensory stimuli. Mice were dissected and underwent
transcardial perfusion with PBS to complete exsanguination. For each mouse,
the liver was removed and separated into three portions: one section was placed
in OCT media and frozen at -80° (for IHC-F), one section as placed in a tissue
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cassette and formalin fixed (for IHC-P), and one portion was flash frozen and
stored at -80° (for RNA extraction). The aorta was removed from surrounding
tissue and placed with the aortic root perpendicular to the bottom of a tissue
cassette and fixed in OCT media and frozen at -80°C.

Developmental timepoint studies:
Female C3H/HeJ (C3H) mice were bred to male C57Bl/6J (Bl/6) mice, and
female mice were monitored for vaginal plugs to estimate the time of fertilization.
Pregnant females were euthanized by CO2 asphyxiation at 17.5 days postconception and the amniotic sac removed. Neonatal pups were euthanized by
decapitation, and pups aged more than 14 days were euthanized by CO2
asphyxiation. All pups were dissected and livers were isolated, frozen, and stored
at -80° C.

Liver Regeneration:
Mouse liver regeneration was induced by a single intraperitoneal injection of
carbon tetrachloride (CCl4). Adult male C3H and Bl/6 mice were administered
either 0.05 ml mineral oil (MO, n=5) or 0.05 ml 10% CCl4 diluted in MO (n=5).
After 3 days, animals were euthanized by CO2 asphyxiation, the livers were
removed, and samples were analyzed by quantitative Real-Time PCR of genes
indicative of hepatic injury.

Murine model of hepatocellular carcinoma:
Female C3H mice were bred to male Bl/6 mice and monitored until pups were
born. At 14 days of age, male offspring were injected with either
diethylnitrosamine (DEN, n=16) or PBS (n=5) at a dose of 10ul/g body weight.
Mice were weaned at 21 days of age and maintained under normal conditions for
36 weeks. Mice were euthanized by CO2 asphyxiation and examined for HCC
tumor development.
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RNA extraction, cDNA synthesis, and Quantitative Real-Time PCR:
Samples were stored at -80° C until needed and then thawed on ice.
Approximately 100 mg of tissue or 106 cells were homogenized in 1 ml RNAzol
RT (Sigma #R4533) and mRNA was extracted according to the product technical
bulletin. Rehydrated RNA was quantified by OD measurement using a NanoDrop
Spectrophotometer (Thermo Scientific). cDNA was synthesized from 1 ug RNA
by the iScript cDNA Synthesis Kit (BioRad #170-8891) per manufacturer’s
protocol. Quantitative Real-Time PCR (qPCR) reactions using SYBR Green PCR
Supermix (BioRad #172-5275) were performed with a CFX96 Touch Real-Time
PCR Detection System and results were analyzed with the CFX Manager
software (BioRad). Oligonucleotide primer sequences are listed in Table 2. qPCR
Ct values were normalized to the ribosomal protein L30 and is reported as
Normalized Expression of the indicated gene. Data shown as Fold Change was
normalized to L30, then values were calculated using the ∆∆Ct method.
Immunohistochemistry:
Dissected mouse tissues were embedded in OCT media (#), flash frozen, and
stored at -80°C. Frozen tissues were acclimated to -20°C and sectioned (10um
thick) using a Microm HM505 N cryostat. Sections were placed onto glass slides,
air dried for 10 minutes, then fixed in 4% paraformaldehyde for 10 minutes.
Slides were washed twice in cold 1xPBS buffer then blocked with the appropriate
serum blocking buffer at room temperature for one hour. Primary antibody
detecting Zhx2 (abcam #96083, 1:250) was incubated overnight at 4°C, washed
twice with 1xPBS, then incubated with secondary antibody (SouthernBiotech
#4010-13, 1:200)for 1.5 hours at room temperature. Slides were mounted with
aqueous mounting media (Dako #2013-05) and covered. Slides were imaged
with a Nikon Eclipse 80i upright microscope with NiS Elements software.

Oil Red O Staining
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Frozen mouse tissues embedded in OCT were sectioned at 10 um thick using a
cryostat. Section were fixed in 10% buffered formalin for 10 minutes then washed
in distilled water for 5 minutes. Slides were submerged in 60% isopropanol for 10
minutes to dehydrate the tissues. Oil Red O stain (Sigma #O0625, 0.5% in 100%
isopropanol) was diluted 3:2 in distilled water and filtered. Slides were stained for
15 minutes while rocking, then washed with 60% isopropanol and counterstained
with hematoxylin. Slides were mounted and covered and visualized Nikon
Eclipse 80i upright microscope with NiS Elements software.

Cell Culture:
Cryopreserved HEK293, Huh7, and HeLa cells were removed from liquid
nitrogen, thawed, and grown in T25 flasks with Dulbecco’s minimal eagle’s media
(DMEM, Corning Cellgro #10-017-CV) supplemented with 10% fetal bovine
serum (FBS, Fisher #03-600-511) and maintained in an incubator at 37°C and
5% CO2.
Expression Plasmid Cloning:
A full-length expression vector for mouse Elovl3 was generated by PCR
amplification (Forward primer: GCCACCATGGACACATCCATGAATTTCTCAC;
Reverse primer: GGATCCTTGGCTCTTGGATGCAACTTTG) of mouse liver
cDNA. Amplicons were cloned into the pGEM-T Easy vector (Promega #A1360),
sequenced, excised using EcoRI and BamHI restriction digests, and cloned into
the pcDNA3.1 expression vector (Invitrogen V790-20). Elovl3 and empty vector
pcDNA3.1 expression plasmids were transformed into competent E. coli cells
using a standard cell transformation protocol. Plasmid preparations were
performed using a Plasmid Max Kit (Qiagen #12165). DNA was quantified by OD
measurement using a NanoDrop Spectrophotometer.

Transfection of Expression Plasmids:
Cells were seeded onto 10 cm2 plates and cultured for 24 hours to obtain 7080% confluence. Transfection reactions using Turbofect reagent (Thermo
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Scientific #R0531) were performed according to the manufacture’s protocol. Cells
were co-transfected with a GFP expression plasmid to visualize transfection
efficiency prior to further experimentation.

Growth in Soft Agar:
Transfected Huh7 cells were cultured for 24 hours, then washed with PBS and
treated with trypsin to lift cells from the plates. Cell suspensions were centrifuged
at 1400 x g for 10 minutes at 4°C, decanted, washed with 1 ml PBS and
centrifuged again, then resuspended in 1 ml PBS. Cells were counted and then
seeded in 96-well plates with media supplemented agar as described [78]. A
feeder layer consisting of 25 ul growth media mixed with 25 ul warm 1.2% agar
(RPI cat #9002-18-0) was added to each well of a 96-well plate and allowed to
solidify. A cell layer of 25 ul 0.8% agar mixed with 5000 cells suspended in
growth media was seeded on top of the feeder layer and allowed to solidify.
Another layer 25 ul growth media with 25 ul 1.2% agar was gently added on top
of the cell layer. The plate was covered and cultured in the cell incubator for one
week. Each sample was plated in triplicate wells, and the experiment was
repeated three times. Cell viability was measured by CellGlo Titer Luminescent
Cell Viability Assay (Promega #G7570) according to the product protocol and
results were read on a luminometer. Sample luminescent values were
normalized to wells containing media and agar layers without cells to account for
background. Luminescent values for control cells were set to 100% and
compared to values of Elovl3 transfected cells in three separate experiments.

Cell Synchronization and Analysis of Cell Cycle:
GFP and Elovl3 or pcDNA3.1 co-transfected cells were cultured for 24 hours
then synchronized by blocking cell growth using a double Thymidine block.
Thymidine dissolved in DMEM was added to plates to a final concentration of 2.5
mM. After incubation for 17 hours, cells were washed three times with PBS and
supplied with fresh growth media for 9 hours. At this time, cells were again
blocked with 2.5 mM Thymidine solution for 15 hours, then washed with PBS.
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Cells were collected at this time (time 0) and at subsequent hourly timepoints.
Cells were fixed overnight in 70% ethanol then washed with 1 ml ice cold PBS
and centrifuged at 1400 x g for 10 minutes at 4°C three times. Cells were
resuspended in 1 ml cold PBS and treated with RNAse A (Sigma #R-5125) at
37°C for 30 min. Cells were stained with propidium iodide (Roche
#11348639001) and strained to remove cell aggregates immediately prior to
analysis by Flow cytometry. Cells were gated for GFP expression then analyzed
for DNA content to estimate the number of cell in each phase of the cell cycle.
Flow cytometry analysis was performed by the Flow Cytometry & Cell Sorting
core facility at the University of Kentucky.

Statistical analysis:
All values within a group were averaged and plotted as mean +/- standard
deviation. p-values were calculated between two groups using student’s t-test
and between three or more groups by ANOVA followed by Tukey’s test. A pvalue less than or equal to 0.05 was considered significant. Data was graphed
and analyzed using GraphPad Prism 6 software.

22

Table 1. Primer Sequences, Genotyping.
Gene

Sequence (5’)

Cre Recombinase

F: ACCTGAAGATGTTCGCGATTATCT
R: ACCGTCAGTACGTGAGATATCTT

LDLr Neo Cassette

F: AGGTGAGATGACAGGAGATC
R: ACCCCAAGACGTGCTCCCAGGATGA
R: CGCAGTGCTCCTCATCTGACTTGT

Zhx2 Floxed Allele

F: GGACCGAATCTCACTATTTAACTCA
R: ACAACGGGTTCTTCTGTTAGTCC
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Table 2. Primer Sequences, qRT-PCR
Gene

Forward

Reverse

AFP
CD36
ChREBP
CPT1A
CPT1B
CPT2
CYP1A1
CYP1A2
CYP2A4
CYP2A5
CYP2B9
CYP2B13
CYP2C40
CYP2D9
CYP2D10
CYP3A16
CYP3A25
CYP4A10
CYP4A12
CYP7A1
CYP8B1
CYP39A
Elovl1
Elovl2
Elovl3
Elovl4
Elovl5
Elovl6
Elovl7
HNF4α
L30
Lpl
MAT1a
PPARγ
STAT5a
STAT5b
SREBP1a
SREBP1c
SREBP2
Zhx2
hCyclin A
hCyclin B
hCyclin D
hCyclin E
hB2M

CCGGAAGCCACCGAGGAGGA
AAAGTTGCCATAATTGAGTCCT
CATCTCCAGCCTCGTCTTC
ACTCGCTGAAGGTGCTGCTCTC
TTCAACACTACACGCATCCC
CACAGCATCGTACCCACCAT
CCGGCATTCATCCTTCGT
ATCCTTTGTCCCCTTCACCAT
GGAAGACGAACGGTGCTTTC
GGA AGACGAACG GTG CTT TT
CCTCGACTACATTGCCCATAG
GCTTTTCTACCCTTCTCCACAG
TGGAAGAGGAAGGATTCCGG
AGAAGTCTCTGGCTTAATTCCTG
GAAGGTCTTCCAAGGTCAGAAG
GATGCCCTCTTTTTGGTTCTGTTGGC
TCCTCTTCACCGAAATCCTGAG
TCCTTAATGACCCTAGACACTG
ATCCTTCTCGATTTGCACCAGG
GGGCTGTGCTCTGAAGTTCGG
CAGAGAAAGCGCTGGACTTC
TGGCTCCTGGCGCTGTTTGAG
GTGGCCCAGCCCTACCTTTGG
TCACCACGCGTCCATGTTCAACA
CCTCTGGTCCTTCCTGGCA
GTGGGTGGCTGGAGGCCAAG
ACTGGGTTCCCTGCGGCCAT
TCCTGTTTTCTGCGCTGTACGCT
TCATGGAGAACCGGAAGCCCTT
GGAAGCTGTCCAAAATGAGCG
ATGGTGGCCGCAAAGAAGACGAA
TGGCTACACCAAGCTGGTGGGA
GGCTGAAATTCCTCAAGGAGTCA
GATTCATGACCAGGGAGTTCCT
CGCTGGACTCCATGCTTCTC
GGACTCCGTCCTTGATACCG
CCGAGATGTGCGAACTGGAC
GGAGCCATGGATTGCACATTTG
GGCGTTCTGGAGACCATG
AGGCCGGCCAAGCCTAGACA
CTGCATCTCTGGGCGTCTTT
TGGTGAATGGACACCAACTCT
GGATGCTGGAGGTCTGCGA
CCCCATCATGCCGAGGGAG
GACTTTGTCACAGCCCAAGATAG

TGGGACAGAGGCCGGAGCAG
AAAGTTGCCATAATTGAGTCCT
CTTGGTCTTAGGGTCTTCAGG
GTGCTGTCATGCGTTGGAAGTC
GCCCTCATAGAGCCAGACC
TGTCTTCCTGAACTGGC TGTC
GCCATTCAGACTTGTATCTCTTGTG
GGGAATGTGGGAAGCCATTCA
TTC CCA GCA TCA TTC TAA GA
TTC CCA GCA TCA TTC GAA GC
GTTCTGGTGATGGAACTCTGTG
ATGTCCTTAGAAGCAACAGGGC
TCACTGTGAAGACCCTTGTGG
GTGGTCCTATTCTCAGTCAACAC
CAGCATTCCCCTTTACCTTCTC
TCAGGTTGGAATTCTTCAGGCTCTGG
TCCTGGGTCCATTTCCAAAGG
TGAAAGATATTCCTCACACGGG
TTCATCGCAAACTGTTTCCCAATG
CACAGAGCATCTCCCTGGAGGG
GGCCCCAGTAGGGAGTAGAC
TGGACTGTATTGACGTGTTTCCGTCT
TGGTAGTTGCAGCTGGGCATGA
AAGCTGTTCAGGGTGGGTCCAA
CGGCGTCATCCGTGTAGATGGC
AGCTGCAGCATGGTCAGGTATCG
TTCCACCAGAGGTAGGGACGCA
GCACCAGTTCGAAGAGCACCGA
AACCTGTACCCCAGCCAGACA
ATG TCG CCA TTG ATC CCA GAG
CCTCAAAGCTGGACAGTTGTTGGCA
GGTGAACGTTGTCTAGGGGGTAGT
GGGCAAAGAGGGAGATAGCG
GGTTGTCTTGGATGTCCTCGAT
GACGTGGGCTCCTTACACTGA
TCCATCGTGTCTTCCAGATCG
GGGAAGTCACTGTCTTGGTTG
CCTGTCTCACCCCCAGCATA
AGGGAAGGAGCTACAAAGTTG
TGAGGTGGCCCACAGCCACT
GTGCAACCCGTCTCGTCTTC
TAGCATGCTTCGATGTGGCA
TAGAGGCCACGAACATGCAAGT
TTATTGTCCCAAGGCTGGCT
TCCATTCCAAATGCGGCATCTTC
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Chapter 3
Hepatic Zhx2 regulates lipid metabolism genes that alter risks of fatty liver and
cardiovascular disease

Introduction
Obesity in the United States is growing in prevalence, with over one-third
of adults and almost one-third of children and adolescents classified as obese
[9]. Obese people face a multitude of adverse health effects, such as
dyslipidemia, diabetes, hypertension, and Metabolic Syndrome, conditions that
increase the risk and prevalence of cardiovascular disease (CVD) and nonalcoholic fatty liver disease (NAFLD). CVD is the leading cause of death of
Americans with close to 800,000 deaths reported annually, and costing an
estimated $320 billion in treatment as of 2011 [21]. Obesity and its comorbidities
have strong associations with high fat diet, physical inactivity, smoking, gender,
race, and age, yet there are numerous contributing genetic factors that are poorly
understood.

Obesity-related NAFLD is characterized by excess lipid accumulation in
the liver, which can lead to inflammation and hepatocyte necrosis and apoptosis,
classified as non-alcoholic steatohepatitis (NASH). Continuing damage and
increased fibrosis in the liver can progress to cirrhosis with declining liver
function. Cirrhosis is a risk factor for the development of hepatocellular
carcinoma (HCC), which is one of the fastest growing cause of cancer deaths in
America [24]. It is estimated that roughly 30% of the American population has
NAFLD, and around 3% of these cases will progress to NASH, then cirrhosis or
HCC [79]. However, almost 90% of obese people have NAFLD, and alarmingly,
the mortality rate from HCC is five times higher in obese men than those of
normal weight [80]. Even without the disease progression to cancer, fatty liver
presents a significant health threat because it contributes to insulin resistance
and diabetes which are features of metabolic syndrome and risk factors for CVD.
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Given the dramatic increase of obese Americans, it is imperative to gain better
understanding of the metabolic disruptions involved in both CVD and NAFLD.
Zinc fingers and homeoboxes 2 (Zhx2) is a eukaryotic transcription factor
identified by the Spear lab as a regulator of gene expression. A natural
hypomorphic mutation in the BALB/cJ Zhx2 gene is responsible for the Hyplip2
phenotype in this strain characterized by lower serum triglycerides and fewer
atherosclerotic plaques when placed on a high fat diet compared to what is seen
in other mouse strains [74]. BALB/cJ mice expressing a liver-specific Zhx2
transgene have elevated serum lipid levels similar to other strains, confirming
that hepatic Zhx2 expression contributes to lipid homeostasis and impacts CVD
risk [75]. Studies in our lab have shown that BALB/cJ mice exhibit increased lipid
accumulation and liver damage than other strains on HFD (Clinkenbeard Thesis,
2011).This is an interesting finding in that BALB/cJ mice develop fatty liver and
yet are protected from CVD, although the two conditions are usually concordant.
Understanding Zhx2 regulation and identification of its targets will provide better
insight into the switch between cardiovascular and hepatic protection seen in
differing Zhx2 status. Notably, two recent human Genome Wide Association
Study (GWAS) identified ZHX2 as an important risk factor for carotid intima
media thickness (cIMT), a subclinical marker of atherosclerosis, although the
functional role of Zhx2 in these cases was not identified [76, 77].
Microarray data indicate Zhx2 may regulate numerous genes involved in
lipid metabolism and transport, including lipoprotein lipase (Lpl), HMG CoA
synthase, Fatty Acid Synthase (FAS), and CD36, among many others. The
findings in BALB/cJ transgenic mice suggest that hepatic Zhx2 expression is
sufficient to reverse the cardio-protective phenotype normally seen in these mice.
As the liver is the major site of lipid metabolism and coordinates many metabolic
processes, it is logical to examine the impact of hepatic Zhx2 on lipid metabolism
genes. However, further exploration of Zhx2 regulation of lipid metabolism in the
liver is limited by the fact that the mutation in BALB/cJ mice is hypomorphic, not
null [81]. BALB/cJ mice continue to express low levels of Zhx2, but only around
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5% of what is seen in other strains of mice. Additionally, Zhx2 is expressed
ubiquitously and therefore Zhx2 and Zhx2-target genes in other tissues could
contribute to the Hyplip2 phenotype. To elucidate the role of hepatic Zhx2
expression on lipid gene regulation, I have developed a hepatocyte-specific Zhx2
knockout mouse line (Zhx2∆hep). The studies described here analyze the impact
of Zhx2 deletion from hepatocytes on lipid metabolism and the resulting impact
on CVD and fatty liver.
Results
Confirmation of hepatocyte Zhx2 knockout
To confirm the establishment of the Zhx2 hepatocyte-specific knockout
mouse line, male mice were genotyped for the expression of Albumin-Cre.
Zhx2∆hep and Zhx2f/f control littermates were housed under normal condition until
6 weeks of age, then euthanized for tissue sample collection. Whole liver RNA
was analyzed by qPCR for the expression of Zhx2 (Figure 5A). Zhx2∆hep mice
had 97% decrease in Zhx2 mRNA compared to littermates. The remaining Zhx2
expression in the RNA sample is likely from other cell types, as Zhx2 remains to
be expressed in Kupffer cells and other non-parenchymal cells in the liver (B
Spear, unpublished obs.). Immunofluorescence staining of frozen liver sections
with antibodies demonstrate Zhx2 proteins localized to the nuclei of hepatocytes
in Zhx2f/f livers (Figure 5C). In contrast, no Zhx2 staining is observed in
hepatocytes of Zhx2∆hep mice, although nuclear staining is still evident in nonparenchymal nuclei (Figure 5D). To confirm further the validity of Zhx2∆hep mice,
we monitored AFP expression, AFP is known to be repressed by Zhx2 and
continues to be expressed in synthesized in adult BALB/cJ liver. RT-qPCR
indicates that AFP mRNA levels are roughly 10-fold higher in Zhx2∆hep mice
compared to Zhx2f/f controls (Figure 5B). These results are similar to what is
observed in BALB/cJ mice, confirming Zhx2∆hep mice provide a valid model to
study hepatic Zhx2 gene regulation.

27

Zhx2 regulates Cyp2a4, Elovl3, and MAT1a
The cytochrome P450 member Cyp2a4 is a female-specific enzyme that
catalyzes the hydroxylation of testosterone [82]. Male BALB/cJ have elevated
expression of Cyp2a4 [83], so we were interested to investigate a connection
with Zhx2. Male Zhx2∆hep mice have a 5-fold increase in hepatic Cyp2a4
expression (Figure 6A). Interestingly, female Zhx2∆hep mice have moderately
reduced Cyp2a4 compared to wildtype female littermates, indicating Zhx2 has a
role in the gender-specific hepatic gene expression (Figure 12, Chapter4). This is
discussed further in Chapter 4.
A potential Zhx2 target gene is Elongation of very long chain fatty acidslike 3 (Elovl3). Elovl3 synthesizes mono-unsaturated and saturated fatty acids
22-24 carbons in length [84]. Elovl3 knockout mice are resistant to diet induced
obesity, which is attributed to increased fatty acid oxidation to support
thermogenesis [85, 86]. Elovl3 expression is reduced by more than 50% in
Zhx2∆hep mice (Figure 6B), making Elovl3 the first identified target of Zhx2 to be
positively regulated. Elovl3 is further described in Chapter 5.
Methionine adenosyltransferase Ia (Mat1a) is involved in the synthesis of
S- adenosylmethionine (SAMe), the sole carbon donor source for DNA
methylation, which is important for epigenetic gene regulation. Mat1a is not
detectable in fetal liver, but its expression increases during development and is
expressed in adult liver. Mat1a is repressed in the regenerating liver and is
greatly reduced in HCC [87]; other Zhx2 targets are also disregulated in these
conditions. Under normal treatment, Mat1a knockout mice develop NASH by 6
months and have spontaneous HCC by 18 months of age [88]. Mat1a mRNA
levels are reduced in the livers of Zhx2∆hep mice, indicating that the Mat1a gene is
positively regulated by Zhx2 (Figure 6C).
Hepatic Zhx2 regulates lipid transport genes Lpl, Cpt1a, and Cd36
Microarray data from livers of BALB/cJ congenic mice with or without the
wild-type Zhx2 gene identified numerous genes involved in lipid metabolism and
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homeostasis as putative Zhx2 targets [75]. We are interested in evaluating these
target genes that are implicated in the control of lipid metabolism. Lpl was of
interest due its known role in lipid disorders in humans. Lpl is usually expressed
on the surface of adipose, skeletal muscle, and other non-hepatic tissues but not
normally expressed in the adult liver. Lpl is activated by ApoCII to hydrolyze fatty
acids from chylomicrons and VLDL particles for energy use or triglyceride
storage within those tissues. qPCR of liver tissue shows that hepatic Lpl
increases nearly two-fold in the absence of Zhx2 (Figure 7A). Lpl is not highly
expressed in the liver, so the increase seen in Zhx2∆hep mice could result in fatty
acid clearance from the serum via increased uptake in the liver. This
disregulation of hepatic Lpl expression provides a possible mechanism for the
BALB/cJ Hyplip2 phenotype.
Studies in our lab have shown that BALB/cJ mice on a HFD have
significantly increased liver lipid accumulation and liver damage compared to
BALB/c mice, which have a normal Zhx2 gene (Clinkenbeard Thesis, 2011). This
suggests that the reduction of Zhx2 results in increased lipid retention in the liver
and a concomitant reduction in serum lipid levels, leading to CVD resistance. The
transport of long chain fatty acids across membranes requires the activity of
various enzymes. The carnitine shuttle consists of three enzymes with
coordinated processes to move long chain fatty acids across the mitochondrial
membrane for beta-oxidation [89]. Carnitine palmitoyltransferase-1 (Cpt1)
replaces the CoA group on long chain fatty acids with carnitine, and the resulting
acyl-carnitine traverses the outer mitochondrial membrane to the inner
membrane space. Carnitine translocase shuttles acyl-carnitine through to the
inner mitochondrial membrane in exchange for a free carnitine recycling back to
the inner membrane space. The carnitine palmitoyltransferase-2 (Cpt2) enzyme
then cleaves carnitine and substitutes CoA to yield fatty acyl-CoA, which is a
substrate for acyl-CoA dehydrogenase in the beta-oxidation pathway. Cpt1a has
two isoforms: Cpt1a is generally expressed in liver, whereas Cpt1b is expressed
in muscle. Zhx2∆hep mice have roughly half the wildtype hepatic expression levels
of Cpt1a (Figure 7C). Cpt1b and Cpt2 expression did not differ between Zhx2∆hep
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and Zhx2f/f mice (Figure 7D, 7E). Cpt1a activity is necessary for the proper
utilization of fats and provides another mechanism to explain the increased liver
lipid accumulation in BALB/cJ mice.
CD36, a fatty acid translocase, is another lipid transport enzyme involved
in the uptake of lipids, including oxidized LDL particles and long chain fatty acids
[90]. CD36 is expressed in hepatocytes and Kupffer cell in the liver, but is
typically more abundant in adipocytes, skeletal muscle, endothelial cells, and
blood cells [91]. CD36 in macrophages facilitates the uptake of long chain fatty
acids and lipoproteins, notably oxidized LDL particles which initiates foam cell
formation and atherogenesis [92]. Expression of hepatic CD36 in Zhx2∆hep mice
is reduced about 45% compared to wildtype mice (Figure 7B).
Zhx2 interactions with other regulators of lipid metabolism
Sterol regulatory element binding-proteins (SREBPs) are critical regulators
of genes that control lipogenesis and therefore of interest as potential
contributors to the Hyplip2 phenotype. SREBP1a activates LDL receptor
expression for increased cholesterol uptake into cells and SREBP1c integrates
insulin signals with lipogenic gene transcription [4]. SREBP2 is a key inducer of
cholesterol biosynthesis [93]. Mutations in the SREBP genes have been
associated with NASH and metabolic syndrome [94]. While these functions might
suggest that SREBP genes could be Zhx2 targets, none of these genes is altered
in Zhx2∆hep mice (Figure 8A-C). Similar to SREBP1c, the carbohydrate response
element binding protein (ChREBP) is a regulator of lipid synthesis in the liver,
though it is activated in response to glucose availability instead of insulin [3, 4] .
ChREBP expression is reduced roughly 50% in Zhx2∆hep mice (Figure 8D).
Zhx2 represses transcription factors HNF4α, STAT5a and STAT5b, and PPARγ
Hepatocyte nuclear factor 4-alpha (HNF4α) is a member of the nuclear
receptors superfamily and is among the most abundant transcription factor in the
liver [95]. HNF4α is a key regulator of lipid metabolism, glucose homeostasis,
and cell differentiation [96, 97] . Because of its importance in the regulation of
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metabolic genes in the liver, we were interested to see if Zhx2 status had any
impact on its expression. Indeed, Zhx2 deletion in hepatocytes lowers Hnf4α
(Figure 9A). Interestingly, liver-specific Hnf4α knockout mice have reduced
serum cholesterol and triglycerides and increased liver lipid accumulation, as is
seen in BALB/cJ mice on HFD [96].
The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear
receptor known for its role in adipocyte differentiation and increased lipid storage
capacity [98]. PPARγ is increased in HFD-induced steatosis [99] and adipose
PPARγ deletion may be protective against HFD insulin resistance [100]. PPARγ
responds to long chain fatty acids to increase triglyceride synthesis and storage
[101]. PPARγ is upregulated in the livers of Zhx2∆hep mice (Figure 9B). This could
contribute to the increased liver damage seen in BALB/cJ on HFD.
We also investigated the impact of Zhx2 on the transcription factors in the
Signal Transducer and Activator of Transcription 5 family, STAT5a and STAT5b.
These factors were identified as essential mediators of growth hormone signaling
and sex-specific gene expression patterns [7]. The disregulation of Cyp2a4 and
other CYP genes in male BALB/cJ [93] and Zhx2∆hep mice (Chapter 4) suggested
a possible interaction with Zhx2. Livers of Zhx2∆hep mice had a modest but
significant reduction in both STAT5a and STAT5b compared to Zhx2f/f mice
(Figure 9C, 9D).
Zhx2∆hep mice on a HFD (preliminary data)
Analysis of altered hepatic gene expression in Zhx2∆hep mice has provided
insight into the Hyplip2 phenotype in BALB/cJ mice. Because BALB/cJ mice
continue to express low levels of Zhx2, one objective of my research is to
examine the impact of complete hepatocyte Zhx2 deletion on cardiovascular
disease risk in mice on HFD. To accomplish this, I bred Zhx2∆hep and Zhx2f/f mice
onto LDLr-/- background. LDLr-/-, Zhx2∆hep and control LDLr-/-, Zhx2f/f littermates
were weaned onto HFD and maintained on the diet for 18 weeks. This study is
ongoing, but preliminary data reveals the hepatic consequences of Zhx2 hepatic
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knockout on HFD. Both cohorts steadily gained weight over the course of the
study. Although not statistically significant, LDLr-/-, Zhx2∆hep have a slightly
greater weight increase than controls (Figure 10A). Completion of the study with
more mice may reveal a difference in weight gain among the groups. H&E
staining of mice livers shows lipid droplets, hepatocyte ballooning, and distorted
morphology in both LDLr-/-, Zhx2∆hep and LDLr-/-, Zhx2f/f mice (Figure 10B). Oil
Red O staining indicates LDLr-/-, Zhx2∆hep have dramatically increased lipid
accumulation compared to LDLr-/-, Zhx2f/f mice, as expected (Figure 10C).
Further analysis in this study will continue to evaluate the liver phenotype and
characterize the cardiovascular phenotype, which will include serum lipid
profiling, aortic root examination for atherosclerotic lesion formation and lipid
accumulation, and IHC to detect CD68 for macrophage infiltration into cardiac
tissue.
Discussion
BALB/cJ mice, which have a natural hypomorphic mutation in the Zhx2
gene, have been instrumental in understanding liver gene regulation and lipid
homeostasis. Studies described in this chapter demonstrate that the Zhx2∆hep
mice will also be valuable in understanding the role of Zhx2 in CVD and fatty liver
disease. Overlapping and sometimes opposing functions of Zhx2-target genes
identified here make understanding the underlying mechanisms of the Hyplip2
phenotype complicated. BALB/cJ mice on a HFD have reduced serum
triglycerides and cholesterol, yet the experience much greater liver lipid
accumulation and damage (Clinkenbeard Thesis, 2011). Increase in hepatic Lpl
expression seen in BALB/cJ and Zhx2∆hep mice presumably have increased fatty
acid uptake into hepatocytes. The decrease in Cpt1a suggests lipids are not
efficiently metabolized in these mice, which could also contribute to increased
lipid accumulation. Additionally, when lipids are not utilized for mitochondrial
beta-oxidation, long chain fatty acids may be shunted to peroxisomes for
degradation [102]. These pathways produce more damaging oxidative
byproducts and could contribute to an inflammatory state and increased liver
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damage in these mice. The impact of decreased CD36 expression in Zhx2∆hep
mice is not as obvious. CD36 null mice on a HFD have increased serum HDL
attributed to increased hepatocyte cholesterol and lipoprotein efflux, conferring a
cardio-protective phenotype in these mice [103]. Another study in CD36 null mice
showed they were resistant to steatosis on a high carbohydrate and alcohol diet
[104]. CD36 null mice under LXR activation exhibited less liver lipid accumulation
than controls [90]. In contrast, CD36 null mice on ob/ob background had reduced
VLDL secretion and greater steatosis [91]. The VLDL output has not been
measured in Zhx2∆hep mice, but future investigation could help elucidate the
impact of diminished CD36. The decrease in Mat1a likely also contributes to the
NAFLD in BALB/cJ mice. In addition to spontaneous NASH and HCC
development, Mat1a null mice also have altered plasma lipid levels marked by
impaired VLDL secretion [87]. The combined impact of these alterations in gene
expression is the increased clearance of serum triglycerides by elevated hepatic
Lpl activity, blockage of beta-oxidation and fat usage for energy, and diminished
secretion of lipids in VLDL. The consequence of these is reduced serum lipids
and corresponding accumulation of lipids in the liver (Figure 11).
Data reported in this study suggest cross-talk between Zhx2 and other
transcription factors that are known regulators of lipid metabolism, adipose
accumulation, liver injury and inflammation. These results implicate Zhx2 as a
contributor to these main lipid regulatory networks and hint to a broader role in
metabolic homeostasis than originally anticipated. The SREBP genes play key
roles in regulating lipid and cholesterol homeostasis in the liver. The fact that
they are not altered in Zhx2∆hep mice is curious but not unexpected as we have
no indications of altered serum glucose levels or insulin sensitivity in these mice.
We have not directly examined these characteristics but would predict that
BALB/cJ mice would not exhibit cardiovascular protection on a HFD if they had
fatty liver as well as altered glucose/insulin responses.
Studies in ob/ob mice, as a model of fatty liver and insulin resistance,
report that ChREBP and SREBP1c synergistically increased after feeding,
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resulting in increased lipogenesis and eventual steatosis [105]. Knockdown of
ChREBP in these mice improved insulin sensitivity and lowered hepatic fat
accumulation and serum triglycerides. Hepatic overexpression of ChREBP in B6
mice maintained insulin sensitivity when placed on HFD, yet had increased
steatosis [106]. The basis for decreased expression in ChREBP in Zhx2∆hep mice
is not clear; analysis of possible changes in serum glucose or insulin response
may provide insight into the relationship between ChREBP and Zhx2.
PPARγ is a well characterized transcriptional activator of genes involved
in adipogenesis and is primarily expressed in adipocytes. An interesting
relationship exists between PPARγ and Elovl3, in that VLCFAs produced by
Elovl3 stimulate PPARγ activity, and PPARγ may increase Elovl3 expression
[107]. Elovl3 expression is ablated in Zhx2∆hep livers, so it would be interesting to
see if it is upregulated in other tissues to compensate for decreased production in
the liver. There is some overlap in substrate response with the other elongase
members, so it is likely that other elongases expressed in the liver are able to
synthesize the VLCFAs that stimulate PPARγ.
HNF4α is well established as a master regulator of hepatic gene
expression and therefore metabolic processes. It is unclear whether HNF4α
responds directly to fatty acid binding or if it is activated by other mechanisms.
The similarity in fatty liver and lower serum cholesterol and triglycerides in
HNF4α liver knockout mice and BALB/cJ mice is consistent with our data that
Zhx2∆hep mice have reduced HNF4α expression. Further analysis of the
interaction of genes regulated by ChREBP, PPARγ, and HNF4α and Zhx2 will
help explain the relationship between these transcriptional regulators and
resulting changes in expression of lipogeneic and adipogenic genes. It will be
interesting to see if Zhx2 directly regulates the expression of these other
transcription factors and thereby is a master regulator of hepatic gene
expression.
To understand the integrated effects of the alterations in these
transcription factors in the livers of Zhx2∆hep mice, a more thorough metabolic
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analysis must be completed. Serum panels to assess insulin and glucose repose
and lipid abundance and content will clarify the role of hepatic Zhx2 in nutrient
sensing responses and lipoprotein production/export. Zhx2∆hep mice should be
analyzed for differences in food intake, absorption and excretion, as well as
alterations in activity level, oxidative capacity, and thermogenesis. Detailed
analysis of the complete metabolic profile of Zhx2∆hep mice will help identify the
impact of altered transcription factor expression seen in the mice and understand
how Zhx2 integrates into established lipid metabolism regulatory networks.
Since Zhx2 is expressed in many tissues, the role of Zhx2 in other tissues,
particularly metabolic tissues such as muscle and adipose, will provide further
insight into Zhx2 and lipid homeostasis.
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Figure 5. Hepatocyte Zhx2 Knockout Mouse Line. Total liver RNA from Zhx2f/f
and Zhx2∆hep littermates was analyzed by qPCR for Zhx2 expression (A) and
AFP (B). Elimination of Zhx2 expression in hepatocytes is confirmed by
immunofluorescence staining which detected positive nuclear Zhx2 in Zhx2f/f (C)
compared to Zhx2∆hep (D). *p<0.05, ***p<0.001.
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Figure 6. Zhx2 regulates hepatic expression of Cyp2a4, Elovl3, and MAT1a.
Zhx2∆hep mice have increased expression of Cyp2a4 (A), normally expressed at
very low levels in male mouse liver. Elovl3 is repressed in Zhx2∆hep (B) and is the
first identified Zhx2 that is positively regulated. MAT1a (C) is repressed in
Zhx2∆hep. *p<0.05, **p<0.01.
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Figure 7. Zhx2 regulates lipid transport genes. Zhx2∆hep mice have increased
expression of Lpl (A), and decreased expression of CD36 (B) and Cpt1a (C). The
alterations in these genes are consistent with the fatty liver phenotype in
BALB/cJ mice. Cpt1b (D) and Cpt2 (E) do not exhibit significant changes in
Zhx2∆hep liver. *p<0.05, **p<0.01.
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Figure 8. Zhx2 regulates other regulators of lipid metabolism. Hepatic Zhx2
expression does not alter the expression of SREBP1a (A), SREBP1c (B), or
SREBP2(C). The glucose-responsive transcription factor ChREBP is significantly
reduced in the livers of Zhx2∆hep mice (D). *p<0.05.
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Figure 9. Zhx2 regulates expression of several hepatic transcription
factors. The liver-enriched factor HNF4α is decreased in the absence of Zhx2
(A), while PPARγ expression is enhanced (B). Signaling effecter genes STAT5a
(C) and STAT5b (D) are modestly reduced in Zhx2∆hep mice. *p<0.05, **p<0.01.
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Figure 10. Preliminary data of LDLr-/-, Zhx2∆hep and LDLr-/-, Zhx2f/f mice on
HFD. LDLr-/-, Zhx2∆hep and LDLr-/-, Zhx2f/f littermates were fed HFD for 18 weeks.
Weight gain is similar in both groups (A). H&E staining of livers shows ballooning
of hepatocytes and triglyceride accumulation indicative of fatty liver in both
cohorts (B). Noticeably increased lipid accumulation is detected in LDLr-/-,
Zhx2∆hep livers by Oil Red O staining (C).
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Figure 11. Impact of Hepatic Zhx2 Deletion. Zhx2∆hep mice have altered
expression of numerous genes important for lipid metabolism. Hepatic Lpl
expression increases triglyceride uptake to the liver. Repression of Cpt1a and
Elovl3 reduces hepatic capacity to metabolize and export lipids and cholesterol
from the liver, increasing retention and damage. Lowered Mat1a may
independently contribute to NAFLD development. Decrease in HNF4α and
increase in PPARγ expression could alter normal hepatic gene regulation on a
global scale. The increase accumulation and reduced export of lipid in the liver
effectively lower serum lipids and reduce atherogenesis.
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Chapter 4
Zhx2 regulates sexually dimorphic CYP gene expression in the adult mouse liver
Introduction
The cytochrome P450 (CYP) supergene family is one of the largest and
most diverse gene families in eukaryotes [108, 109]. CYP genes encode
structurally related enzymes that catalyze a variety of metabolic reactions,
including metabolism of steroid-based hormones, lipids, drugs and environmental
chemicals [110]. In humans, mutations in CYP genes contribute to a variety of
metabolic diseases [111], and polymorphisms in CYP genes are a major
contributor to variations in susceptibility to xenobiotics [112, 113]. The CYP
supergene family arose through numerous duplication events. In vertebrates, the
number of CYP genes and pseudogenes vary dramatically between different
species. Analysis of genome databases suggests that humans contain 57
functional CYP genes and 58 pseudogenes, whereas mice contain 102 functional
CYP genes and 88 pseudogenes.
CYP genes exhibit a variety of expression patterns. Some CYP genes are
expressed in numerous tissues, whereas expression of other CYP genes is more
highly restricted to one or several tissues. The liver has the highest level of CYP
expression, which is not surprising since ingested xenobiotics enter the liver
before circulation elsewhere in the body. Numerous drugs and xenobiotics can
induce CYP gene expression; much of this is governed by members of the
nuclear receptor family, including the Constitutive Androstane Receptor (CAR),
aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), and peroxisome
proliferator activated receptor α (PPARα) [114]. As with structural
polymorphisms in CYP enyzmes, variation in the expression and induction of
CYP enzymes in response to xenobiotics can lead to different responses to these
agents. These variations must be considered when comparing the metabolism
and toxicity of drugs and environmental chemicals between different humans as
well as different species such as mice and humans [115].
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One common feature of many vertebrate CYP genes is sexual dimorphic
expression [116]. Many CYP genes, including Cyp 2d9 and Cyp4a12, are
expressed primarily in males [117]. In contrast, other CYP genes such as
Cyp2b9 and 2b13 show a female-biased pattern of expression [117]. The degree
of sex-biased expression varies considerably. Differences in circulating Growth
Hormone (GH) levels play an important role in this sexually dimorphic expression
[118]. In the liver, the transcription factors STAT5a/b and hepatocyte nuclear
factor 4α (HNF4α) help govern gender-specific expression [8, 119, 120].
A dramatic example of sexually dimorphic expression is seen with the
Cyp2a4 gene in mice. In normal adult liver, the mouse Cyp2a4 gene is
expressed abundantly in female livers with very low hepatic expression in adult
males [121]. Curiously, Cyp2a4 expression in adult male BALB/cJ mice is almost
equal to what is seen in female mice [83] . The high Cyp2a4 mRNA levels
observed in BALB/cJ males is an autosomal recessive trait. This led to the
suggestion that the absence of Cyp2a4 expression in male mice is due to a
transcriptional repressor, and that a mutation resulting in the loss of this putative
repressor in BALB/cJ mice results in de-repression of Cyp2a4 in adult BALB/cJ
male liver.
Several years ago, we identified Zinc fingers and homeoboxes 2 (Zhx2) as
a regulator of gene expression in the postnatal liver. Several Zhx2 target genes,
including alpha-fetoprotein (AFP), H19, and Glypican 3 (Gpc3) are expressed
abundantly in the fetal liver and dramatically repressed in the first several weeks
after birth [29, 81]. In contrast to most strains of mice, AFP, H19 and Gpc3
continues to be expressed in the adult liver of BALB/cJ mice. The continued
expression of these genes in BALB/cJ liver, where adult liver AFP mRNA levels
are 10- to 20-fold higher than other mouse strains, is an autosomal recessive trait
regulated by a locus on Chromosome 15. Using positional cloning, we found that
elevated AFP, H19 and Gpc3 mRNA levels in BALB/cJ livers was due to a
hypomorphic mutation in the Zhx2 gene that dramatically reduces Zhx2 levels.
Interestingly, when placed on a high fat diet, BALB/cJ mice have fewer serum
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triglycerides and reduced atherosclerotic lesions compared to other mouse
strains on the same diet. This strain difference is also due to the Zhx2 mutation,
and several proteins involved in lipid/cholesterol homeostasis are disregulated in
BALB/cJ livers. Taken together, these data indicate that Zhx2 is an important
regulator of numerous hepatic genes in the adult liver.
Zhx2 is a member of a small gene family that also contains Zhx1 and
Zhx3. The Zhx proteins contain two amino-terminal C2-H2 Zinc fingers and four
(or five, in the case of Zhx1) carboxy-terminal homeodomains. In vitro studies
suggest that Zhx proteins function as transcriptional repressors. This, along with
the fact that the Zhx2 gene is mutated in BALB/cJ mice, led us to investigate
whether the mutation in Zhx2 could account for elevated Cyp2a4 expression in
adult male BALB/cJ mice. Using several mouse models, our data indicate that
Cyp2a4 is a target of Zhx2 repression. In contrast to Cyp2a4, expression of the
highly related Cyp2a5 gene shows little change in the absence of Zhx2.
Furthermore, we demonstrate that numerous other sex-biased CYP enzymes
exhibit altered expression in the absence of Zhx2. In general, female-biased CYP
enzymes exhibit increased expression in males but male-biased CYP enzymes
show little change in either sex. Levels of Cyp7a1 mRNA, which is present at
high levels in both male and female liver, are increased in males and reduced in
females in the absence of Zhx2. This data indicates that Zhx2 is an important
regulator of sex-specific expression of CYP enzymes in the liver.
Results
Cyp2a4 mRNA levels are higher in the liver of male Zhx2∆hep mice
Cyp2a4 is normally expressed at high levels in adult liver of female mice but not
expressed in adult male liver. An exception to this is seen in BALB/cJ mice, in
which Cyp2a4 mRNA levels are almost equal in both male and female adult liver.
We asked whether Zhx2, which is mutated in BALB/cJ mice, could account for
this strain-specific trait. To accomplish this, we analyzed Cyp2a4 expression in
BL/6 mice with a hepatocyte-specific deletion of Zhx2. Mice with a floxed Zhx2
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allele (described in Chapter 2) were bred with Albumin-Cre (Alb-Cre) transgenic
mice to generate mice that were homozygous for the floxed Zhx2 gene and AlbCre+ (Zhx2∆hep); floxed homozygous littermates that did not contain the Alb-Cre
transgene (Zhx2f/f) were used as controls. Zhx2 is efficiently silenced in the
hepatocytes of Zhx2∆hep mice but still expressed in non-parenchymal cells
(Chapter 3, Figure 5). In control Zhx2f/f mice at 5 weeks of age, Cyp2a4 is
expressed in females but barely detectable in males as expected. In contrast,
Cyp2a4 mRNA levels are increased nearly 90-fold in age matched Zhx2∆hep male
mice to levels that are comparable to those seen in female Zhx2∆hep adult liver,
which show a ~40% reduction in Cyp2a4 levels compared to Zhx2f/f females
(Figure 12A, B). These data indicate that Zhx2 is responsible for the low Cyp2a4
levels in adult male mice. Interestingly, Cyp2a5, which is highly related to
Cyp2a4, does not exhibit sex-biased expression or significant differences
between Zhx2∆hep and Zhx2f/f mice.
Cyp2a4 levels exhibit gender-specific changes in the postnatal liver
Previously identified Zhx2 targets, including AFP, H19 and Gpc3, are expressed
abundantly in the fetal liver and silenced after birth. In contrast to Cyp2a4, these
genes do not exhibit gender-biased expression. This led us to investigate
Cyp2a4 in the fetal liver and postnatal patterns of Cyp2a4 expression in male
and female wildtype mice. In both sexes, Cyp2a4 levels are very low in the e17.5
liver and show a gradual increase during the first four weeks after birth. A
modest increase in Zhx2 mRNA levels is also seen at this time (Figure 13A, B).
However, the gender bias in the liver is evident at p28, with female Cyp2a4 levels
roughly 8-fold higher than that seen in males (Figure 13C, D). A dramatic change
in this pattern occurs between four weeks and eight weeks of age. In male mice,
Zhx2 levels increase roughly 6-fold during this period (Figure 13A), whereas
Cyp2a4 levels are dramatically reduced to barely detectable levels (Figure 13C).
In contrast, Zhx2 and Cyp2a4 levels show modest changes in the female liver
during this time period (Figure 13B, D). This data supports the possibility that
Zhx2 contributes to Cyp2a4 silencing in the adult male liver, and that full
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repression is associated with sexual maturity that occurs between 4 and 8 weeks
of age.
A number of CYP enzymes in addition to Cyp2a4 exhibit gender-specific
expression, with some being expressed at higher levels in male and others in
females. Since male-specific Cyp2a4 mRNA levels increased in Zhx2∆hep mice,
we evaluated expression of other hepatic Cyp enzymes in the presence or
absence of Zhx2. Eight Cyp genes that are normally expressed at higher levels in
females were examined. In general, the loss of hepatic Zhx2 resulted in
increased expression in adult male liver (Figure 14). The increase was robust in
several cases (27-fold and 9-fold for Cyp2b13 and Cyp2b9, respectively) and
more modest for other enzymes (2- to 3-fold for Cyp4a10, Cyp2c40, Cyp 3a16
and Cyp39a). Zhx2 did not affect expression of Cyp1a1 or Cyp1a2 in males.
Expression of these genes was the same or slightly less in females Zhx2∆hep
mice than in Zhx2f/f only This pattern is similar to what was seen with Cyp2a4
(Figure 12). A different pattern was seen with several male-biased Cyp enzymes.
In two that were analyzed, Cyp2d9 and Cyp8b1, showed little change in either
sex in Zhx2∆hep liver compared to Zhx2f/f liver (Figure 15). Cyp4a12 was
repressed in female Zhx2∆hep mice. Three Cyp enzymes that are expressed
equally in both sexes were examined (Figure 16). Cyp3a25 and Cyp2d10 did not
respond to the loss of Zhx2 whereas Cyp7a1 was slightly increased in males and
decreased in females. Interestingly, Cyp7a1 codes for the rate-limiting enzyme
that converts cholesterol to bile acids so alterations in its expression likely affects
cholesterol metabolism.
Cyp2a4 mRNA levels are increased in HCC
Previously identified genes that are repressed by Zhx2, including AFP,
H19 and Gpc3, are silent in the healthy adult liver but frequently reactivated in
HCC. Since Cyp2a4 also appears to be negatively regulated by Zhx2, we asked
whether it was also disregulated in HCC. Analysis of RNA from normal C3B6F1
male mouse liver and male HCC tumors induced by DEN (described in Chapter
2) indicated that Cp2a4 levels were significantly increased in tumors (Figure 17).
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Discussion
Data in this chapter provide the first evidence that Zhx2 contributes to
gender-biased gene expression in the adult liver. The sexually dimorphic
expression of CYP genes is well documented, but the involvement of Zhx2
regulation of genes in a sex-specific manner provides a link between
developmental gene regulation and gender-biased expression. Zhx2 represses
targets AFP, H19, and Gpc3 in normal adult mouse liver, and these genes have
similar expression levels in males and females. Zhx2 positively regulates Elovl3
in mouse liver during development (discussed in Chapter 5). After sexual
maturity, Elovl3 is more abundant in male liver, and is expressed in a circadian
rhythm only in male liver [122]. Data presented here shows that Zhx2 positively
regulates Cyp2a4 in male and female liver during development, but between 4-8
weeks of age, Zhx2 is required for full Cyp2a4 repression in male liver.
Cyp2a4 and other Cyp enzymes, along with Elovl3, exhibit circadian
patterns of expression. Cyp2a4 circadian regulation in male mice is attributed to
integration of growth hormone (GH) signaling via STAT5 activation [8, 123].
STAT5b expression is necessary for expression of male-specific Cyp genes,
whereas both STAT5a and STAT5b expression are required for female gene
patterning [119]. The expression of the appropriate STAT5 isoforms coordinates
the expression of genes in a sex-specific manner in response to GH signaling.
GH is expressed in a pulsating manner in males while females have more steady
GH circulation [120]. HNF4α is a key regulator of gene expression in the liver.
Almost half of actively transcribed hepatic genes containing response elements
[95], suggesting that HNF4α affects more target genes than other hepatic
transcription factors. Studies in HNF4α-deficient mice showed this factor to be
necessary for the expression of several sex-specific Cyps [124]. A current model
of integration of HNF4α with GH signaling suggests the pulsating spike in GH in
male mice activates STAT5b, and possibly HNF4a, which translocate to the
nucleus and increase transcription of male specific Cyp genes (Figure 18).
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Increased HNF4a suppresses HNF6 and HNF3β which are associated with
expression of female Cyps. The continuous GH levels in females correspond with
increased HNF6 and HNF3β activity and fail to activate STAT5b and therefore
fail to activate male Cyp expression [124, 125]. These combined studies indicate
that GH pulses and activation of STAT5b and HNF4α are critical to male Cyp
expression. Interestingly, qPCR data in Zhx2∆hep mice suggest hepatic Zhx2
deletion reduces the expression of HNF4α, STAT5a, and STAT5b (Chapter 3).
As each of these transcription factors is a critical component of sex-specific gene
regulation, the reduction in Zhx2∆hep mice could help explain the disregulation of
multiple Cyp genes in the livers of both male and female Zhx2∆hep mice. Further
examination into the potential interaction of Zhx2 with HNF4α and STAT5 is
warranted by these findings, and could elucidate the mechanism by which sexbiased genes are regulated in the liver.
We provide evidence that Cyp2a4 is activated in HCC, similarly to other Zhx2
targets. Disregulated expression of various CYP genes has been associated with
human liver disease risk. Data from human tissue arrays of HCV infected, HCV
infected with HCC, and non-HCV normal livers identified differential expression of
27 different CYPs depending on disease state and severity [126]. The pattern of
expression varies; CYP2C9 is lower in HCC cases with larger tumors, whereas
CYP51A1 increases with tumor size. CYP2B6, CYP2C9, CYP2C19, CYP3A5,
CYP4F3, CYP27A1, CYP2E1, and CYP4F2 were lower in HCC with greater
vascularization and thus more advanced progression [126]. A qRT-PCR panel of
numerous CYPs revealed that HCC tissues generally have lower CYP
expression than non-tumor tissue; however, HCC samples that overexpress one
CYP gene usually exhibit higher expression of several CYPs [127]. Diminished
CYP2E1 has been associated with increased tumor aggression and poor
prognosis in HCC patients [128]. These studies confirm that CYP expression is
often disregulated in HCC and the degree of disregulation could correlate with
the advancement of disease. Data from our collaborator [35] indicates that
nuclear Zhx2 levels are reduced in HCC samples compared to non-tumor liver
tissue, suggesting that this differential localization of Zhx2 could account for the
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lack of repression of Zhx2 targets in HCC. Additional studies will be needed to
further explore whether reactivation of CYP enzymes in cancer is due, at least in
part, to changes in Zhx2.
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Figure 12. Zhx2 regulates Cyp2a4 in a gender-specific manner. Adult male
Zhx2∆hep mice have 90-fold increase in Cyp2a4 expression (A), whereas female
Zhx2∆hep have about 40% reduced expression (B) when compared to Zhx2f/f
controls. This data suggests Zhx2 positively regulates Cyp2a4 in female mouse
liver and represses it in adult male liver. *p<0.05.
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Figure 13. Zhx2 regulation of Cyp2a4 during development. Liver RNA
extracted from C3B6F1 offspring at development timepoints was analyzed by
qRT-PCR. Zhx2 expression increases with age in both male (A) and female (B)
offspring until d28. Zhx2 levels continue to increase in male mice from d28 to
d56. Cyp2a4 expression is positively regulated in males (C) and females (D) until
d28. Around sexual maturity at d56, male mice have almost complete repression
of Cyp2a4 while females continue to express it. Developmental expression
compared to e17.5, *p<0.05, **p<0.01, ***p<0.001.

52

Figure 14. Zhx2 regulation of female-specific Cyps. Eight Cyp genes
characterized as being more abundant in females were analyzed. Liver mRNA
was analyzed by qRT-PCR in Zhx2f/f and Zhx2∆hep littermates. Although not
statistically significant, expression trends are apparent. Two genes, Cyp2b13 (C)
and Cyp2b9 (G) increased dramatically in male Zhx2∆hep mice. Cyp4a10 (A),
Cyp3a16 (B), Cyp39a (D) and Cyp2c40 (E) increased modestly in male Zhx2∆hep
mice. Cyp1a1 (F) and Cyp1a2 (H) did not differ with Zhx2 status. Cyp1a2 (H)
was lower in female Zhx2∆hep mice; hepatic Zhx2 expression did not affect
expression of other female biased CYPs. *p<0.05.
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Figure 15. Zhx2 regulation of male-specific Cyps. Three Cyp genes typically
more abundant in males were analyzed by qRT-PCR. There is no difference in
expression in male Zhx2∆hep mice from controls. Female Zhx2∆hep mice had lower
expression of Cyp4a12 (B) and Cyp8b1 (C). *p<0.05 , ****p<0.0001.
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Figure 16. Zhx2 regulation of gender-neutral Cyps. Analysis by qRT-PCR of
Cyp genes expressed equally in males and females indicated hepatic Zhx2 does
not alter their expression in males. Cyp7a1 (C) was reduced in female Zhx2∆hep
mice. *p<0.05.
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Figure 17. Cyp2a4 is disregulated in HCC. B6C3F1 male mice were injected
with DEN (n=15) or PBS (n=5) to induce HCC tumor formation. Samples were
collected 36 weeks post-injection. Tumor samples had 40-fold higher Cyp2a4
than control liver. ****p<0.0001.
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Figure 18. Zhx2 involvement in Growth hormone-STAT5 signaling to
regulate gender-specific CYP expression. Female mice have continuous
growth hormone (GH) signaling that activates STAT5a and STAT5b
heterodimers to promote female-specific CYP expression. Male mice have GH
pulses that activate STAT5b homodimers, possibly coordinated with HNF4α, to
activate male-specific CYP genes and cause repression of female-specific CYPs.
Our data suggest Zhx2 may be the male-specific repressor of female CYPs,
explaining the elevated female-specific CYP expression in exhibited in male
Zhx2∆hep mouse livers.
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Chapter 5
Zhx2 regulates hepatic Elovl3, a fatty acid elongase with tumor suppressor
qualities
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer
globally, and is the third leading cause of cancer deaths [129]. The prevalence of
HCC in the United States is relatively low compared to other cancers and is
primarily attributed to alcoholic liver disease and infection with Hepatitis C Virus
(HCV) and, to a lesser extent, with Hepatitis B Virus (HBV) [130]. In the past
several decades, there has been a surge in both cases and deaths from HCC in
the U.S., and a large portion are correlated with the increasing rates of obesity
and Type 2 Diabetes [15, 131] With the expected increase of obesity and
associated clinical manifestations, the incidence of HCC is expected to increase
and be the third leading cause of cancer deaths in the United States by 2030
[24]. The high death rate resulting from HCC is due in part to a lack of early
detection methods and poor understanding of early events in the progression of
the disease. Currently, the most commonly used detection method for liver
damage is serum screening for elevated alpha-fetoprotein (AFP). AFP has been
used as a diagnostic marker for liver damage and possible HCC for over 40
years [132]. AFP is expressed abundantly in the fetal liver, dramatically
repressed at birth, and reactivated in liver damage and liver cancer, and thus
was the first identified and well-characterized HCC oncofetal protein.
In contrast to other mouse strains, AFP continues to be expressed in the
adult liver of BALB/cJ mice. This recessive trait has provided the basis for studies
on postnatal AFP regulation and enabled us to identify the genetic basis for
persistent AFP expression [26]. By positional cloning, we found that the loss of
postnatal AFP repression was due to a hypomorphic mutation in the BALB/cJ
Zinc fingers and homeoboxes 2 (Zhx2) gene [31, 81]. Several other genes that
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are expressed abundantly in the fetal liver and repressed at birth, including H19,
Glypican 3 (Gpc3), and Lipoprotein lipase (Lpl, unpublished), are also expressed
in BALB/cJ adult liver; these genes are also targets of Zhx2 [29, 81].
Interestingly, all of these targets are also frequently reactivated in HCC. While
AFP and Gpc3 are used clinically as diagnostic markers, a functional role for
these proteins in HCC cause or progression has not been demonstrated. Due to
the fact that AFP, H19 and Gpc3 are reactivated in HCC, there is interest in
identifying other Zhx2 targets that might contribute to HCC progression and/or
serve as biomarkers of liver disease.
Microarray data provided by our collaborator, Jake Lusis (University of
California, Los Angeles) identified Elongation of very long chain fatty acids-like
3 (Elovl3) as a potential Zhx2 target. Elovl3 is a member of a family of seven
mammalian fatty acid elongases (Elovl1-7) that are required for de novo
synthesis of very long chain fatty acids (VLCFAs) up to 24 carbons in chain
length [84]. Each elongase in this family has distinct tissue distribution and
substrate specificity, making them important regulators of cellular lipid
composition as well as specific cellular functions [133]. The Elovl3 enzyme
synthesizes C20-C24 saturated and monounsaturated fatty acids and is most
abundantly expressed in skin sebaceous glands, brown and white adipose, and
the liver [133]. Prior reports indicate Elovl3 in the skin is imperative for proper
barrier function [134] and is important in brown fat for activation of thermogenesis
in response to cold exposure [135]. However, the role of Elolv3 in the liver has
not been investigated. Here, using several mouse models, we tested whether
Elovl3 is a target of Zhx2. Our data indicate that Elovl3 is controlled by Zhx2. In
contrast to other Zhx2 targets that are silenced in the postnatal liver and
repressed by Zhx2, hepatic Elovl3 mRNA levels increase after birth and are
positively regulated by Zhx2. This led us analyze Elovl3 mRNA levels in
regenerating liver and in HCC. We find that Elovl3 levels decrease in a mouse
models of liver regeneration and in mouse liver tumors. Based on these data, we
investigated whether the loss of Elovl3 has a causal role in HCC progression. We
have found that forced Elovl3 expression reduces growth of human hepatoma
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cells in soft agar. Consistent with this, flow cytometry indicates that Elovl3 alters
cell cycle progression and expression of cyclins. Studies by our collaborators in
China indicate that Elovl3 mRNA levels are significantly decreased in human
HCC samples compared to adjacent non-tumor regions. Taken together, this
data indicates that Elovl3 might function as a tumor suppressor in HCC and is a
novel biomarker of HCC in humans.
Results
Hepatic Elovl3 mRNA levels are reduced in the absence of Zhx2.
Microarray data suggested that Elovl3 might be a target of Zhx2. However,
in contrast to previous Zhx2 targets that are higher when Zhx2 levels are
reduced, Elovl3 levels appear to be decreased when Zhx2 levels are lower. This
suggests that Elovl3 is positively regulated by Zhx2. To explore this further,
studies were carried out in mice in which the Zhx2 gene was deleted in
hepatocytes (Zhx2∆hep) mice and littermate controls (Zhx2f/f) (described in
Chapters 2 and 3). To confirm the reduction in Zhx2 levels, qPCR was performed
with cDNA from Zhx2∆hep and control Zhx2fl/fl mice (Figure 19). Zhx2 mRNA levels
in 5 week old Zhx2∆hep mice were roughly 3% the levels seen in Zhx2f/f
littermates, consistent with deletion of the Zhx2 gene in hepatocytes (Figure
19A). The remaining Zhx2 expression in Zhx2∆hep liver is likely due to Zhx2
expression in non-parenchymal cells where Alb-Cre is not active. Elovl3 mRNA
levels were also significantly reduced in Zhx2∆hep livers (Figure 19B), indicating
that Elovl3 is the first gene positively regulated by Zhx2.
Elovl3 is developmentally activated in the perinatal mouse liver.
Previously identified Zhx2 targets, including AFP, H19 and Gpc3, are
silenced in the liver after birth and repressed by ZHx2. In contrast to these
genes, Elovl3 appears to be positively regulated by Zhx2. This suggests that
Elovl3 might be developmentally activated during the perinatal period. To test
this, livers were removed from C3B6F1 mice at e17.5 and postnatal day 1 (p1),
p7, p14, p21, p28 and p56. Since Elovl3 is expressed at higher levels in adult
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male mice than in female mice, studies were performed in both sexes. RNA was
extracted and analyzed by RT-qPCR for Zhx2 and Elovl3. Hepatic Zhx2 mRNA
expression is very low but detectable at e17.5 and gradually increased in both
male and female livers until p28 (Figure 20A, B). However, Zhx2 levels remain
relatively constant in female mice for the next four weeks, but increased roughly
6-fold in male mice between p28 and p56, suggesting that this male-specific
Zhx2 increase between four and eight weeks coincides with sexual maturity.
Elovl3 in male liver also showed a gradual but modest increase between e17.5
and p28 (Figure 20C). In female livers, Elovl3 levels remain relative constant until
p21 but increased somewhat by p28 (Figure 20D). Interestingly, at p28, Elovl3
mRNA levels are 10-fold higher in female than in males. However, between p28
and p56, hepatic Elovl3 levels increase ~10-fold in males and decrease ~20-fold
in females. The dramatic rise in Elovl3 in male mice between p28 and p56
coincides with the increase in Zhx2, whereas Elovl3 levels decrease in females
during this period even though Zhx2 levels stay relatively constant. This data
indicates that male-biased Elovl3 expression is established between 1 and 2
months of age.
Zhx2 regulation of elongase family members in adult liver.
The seven mammalian elongases (Elovl1-7) are similar in sequence and
structure, and there is some overlap and redundancy in their enzymatic activities
[84, 133]. Due to the strong impact Zhx2 expression has on Elovl3, we examined
whether expression of the other elongases at four weeks of age changed in the
absence of Zhx2. Elovl1 mRNA levels were significantly lower in Zhx2∆hep liver.
Elovl5 and Elovl6 showed this same trend but the difference between Zhx2∆hep
and Zhx2f/f livers did not reach significance. Elovl2 showed no change of
expression. Elovl4 and Elovl7 are not normally expressed in the liver and were
not detected in these samples (Figure 21 and data not shown).
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Elovl3 is repressed in the regenerating liver, and controlled by Afr2.
Hepatocytes are normally quiescent in the adult liver, but have the ability
to re-enter the cell cycle after injury to restore the liver to its original size and
function [136]. This regenerative capacity is of great importance since a number
of drugs and environmental chemicals are toxic to hepatocytes. Carbon
tetrachloride (CCl4) is a well-studied hepatotoxin that induces liver regeneration.
In adult mice, an intraperitoneal injection of 5 ul of CCl4 will kill roughly 70% of
hepatocytes, and over a 5-7 day period after this insult the liver will regenerate to
its normal size. All known targets of Zhx2, including AFP, are silent in the healthy
adult liver but are transiently reactivated during liver regeneration, with peak
expression occurring ~3 days after injury. Reactivation of these Zhx2 targets is
lower in BL/6 mice than in other mouse strains. This low AFP induction in BL/6
mice is a dominant trait governed by a single locus on mouse Chromosome 2
called Alpha-fetoprotein regulator 2 (Afr2). Since every known target of Zhx2 is
regulated by Afr2, we tested whether Elovl3 mRNA levels changed in
regenerating liver and also be regulated by Afr2. Liver regeneration was initiated
in C3H and BL/6 mice by a single IP injection of CCl4 in mineral oil, or mineral oil
alone as control. Mice were killed and livers removed 72 hours post-injection. As
expected, AFP levels were low in both strains when treated with mineral oil,
whereas the AFP induction was much higher in C3H mice than in BL/6 mice
(Spear lab, unpublished). Elovl3 levels were about the same in both strains
treated with mineral oil. After CCl4 treatment, Elovl3 mRNA levels were reduced
but the extent of reduction was greater in C3H than in BL/6 mice. Since Elovl3
regulation by Zhx2 is opposite what is seen with AFP, It is not surprising that
Elovl3 levels decreased, rather than increased, in regenerating liver. The more
robust repression of Elovl3 in C3H compared to BL/6 liver indicates that Elovl3 is
also regulated by Afr2 during liver regeneration.
Elovl3 is repressed in a mouse model of HCC.
While the liver regeneration in response to a single insult is a short-term
proliferative response, persistent damage and/or treatment with mutagenic
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agents can lead to tumor formation [137]. AFP and all other Zhx2 targets are
classified as oncofetal genes in that they are expressed in fetal tissues,
developmentally silenced at birth, and reactivated in cancer, including
hepatocellular carcinoma (HCC). The dramatic reduction in Elovl3 during liver
regeneration led us to ask if Elovl3 is also repressed in HCC. Male B6C3F1 mice
were treated with the tumor initiator DEN. After 36 weeks, mice were killed.
Those receiving no DEN had no tumors, whereas all DEN-treated mice had
multiple tumors. qRT-PCR analysis showed an almost complete repression of
Elovl3 expression in tumors (Figure 22A). Other elongase family members also
exhibited altered expression in tumors (Figure 22B), but not to the same extent
as Elovl3. Elovl2 expression increased over two-fold in tumor samples, whereas
Elovl6 expression was decreased roughly 60%.
Elovl3 expression reduces anchorage-independent cell growth and stalls cell
cycle progression in S phase.
Loss of Elovl3 mRNA and protein expression during liver regeneration and
in HCC tumors led us to consider whether Elovl3 may influence cell proliferation.
Anchorage independent cell growth is a noted feature of transformed cells, which
can be measured by growth in soft agar. We examined the effect of Elovl3
expression in Huh7 cells, a human HCC cell line that has negligible endogenous
Elovl3 expression. Cells transfected with expression plasmids for either Elovl3 or
pcDNA3.1 empty vector were seeded at 5000 cells per well in mediasupplemented soft agar, cultured for one week, and measured by a luminescent
viability assay. Elovl3 transfected cells exhibit 35% reduced growth compared to
pcDNA3.1-transfected control cells (Figure 23). A similar (~30%) reduction in cell
growth was seen in Elovl3-transfected Huh7 cells grown as monolayers (data not
shown).
This data led us to look more closely at Elovl3 and cell cycle progression.
Hela cells were transfected with a GFP expression plasmid along with Elovl3
expression vector or control pcDNA3.1 and synchronized. Cells were then
analyzed by flow cytometry at various times after release from the double63

thymidine block. Propidium iodide (P.I.) staining of GFP-positive cells indicated
that as early as one hour after release, Elovl3 expression results in fewer cells in
G2 and an increased proportion of cells in S phase when compared to
pcDNA3.1-transfected cells (Figure 24). This trend continued to hold for the first
8 hours after release; control cells begin to progress to G2 roughly three hours
after release whereas Elovl3 cells do not show noticeable G2 progression until 5
hours, suggesting that Elovl3 stalls cells in the S phase.
The cell cycle is a tightly regulated process that requires the coordinated
expression of several cyclins at varying points in the cycle, as well as the
association of the appropriate cyclin-dependent kinase (CDKs) [138]. Previous
studies have shown that Zhx2 regulates the expression of cyclins E and A [35],
which are necessary for the proper progression of cells from G1 to S-phase and
S-phase to G2, respectively. As Zhx2 regulates Elovl3 and our data indicate that
Elovl3 reduces cell proliferation and alters the cell cycle, we next examined the
effect of Elovl3 on cyclin expression at the hourly timepoints after cell
synchronization. Cyclins D, E, A, and B mRNA levels are similar in Elovl3transfected and pcDNA3.1-transfected control cells until hour 3 (Figure 25). At
this time, control cells show a surge in expression of Cyclins D, E, and A, and a
modest increase in Cyclin B. The increased cyclin expression coincides with the
increased number of cells progressing to G2 at this timepoint. In contrast, the
surge in Cyclins E, A and B in Elovl3-transfected cells is delayed until hour 5.
Elovl3-transfected cells do not exhibit a surge in Cyclin D that is seen in control
cells.
Discussion
Identification of Zhx2 was based on the continued expression of AFP and
other fetal genes in the adult liver of BALB/cJ mice. This and additional studies
indicate that Zhx2 is a repressor of AFP and other target genes that are silenced
at birth. Data shown in this chapter indicate that Elovl3 is also a target of Zhx2. In
contrast to other targets, Elovl3 is the first gene that appears to be positively
regulated by Zhx2. Our data show that Elovl3 levels are significantly reduced in
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Zhx2∆hep mice compared to Zhx2f/f control littermates (Figure 19). Consistent with
this data, Elovl3 levels are higher in BALB/cJ mice that express a liver-specific
Zhx2 transgene than in non-transgenic BALB/cJ littermate controls (Spear lab,
unpublished). In addition, Elovl3 mRNA levels increase during the first four
weeks after birth, a time when Zhx2 mRNA levels are also increasing (Figure 20).
In vitro studies by our collaborators in China indicate that endogenous Elovl3
mRNA levels in human hepatoma cell lines increase in Zhx2-transfected cells,
whereas these Elovl3 levels decrease when Zhx2 levels are reduced by miRNA
knock-down (Ma et al, unpublished). While these studies indicate that Elovl3 is
positively regulated by Zhx2, they do not distinguish whether this regulation is
direct or indirect. Further studies, including ChIP, will be needed to distinguish
between these possibilities and to identify the cis-acting site(s) in the Elovl3
regulatory region required for Zhx2 responsiveness. It should also be noted that
nuclear run-on studies performed in Dr. Peterson’s lab indicate that Zhx2 might
act, at least in part, at the post-transcriptional level. Thus, further studies will be
needed to fully understand the mechanism by which Zhx2 regulates target gene
expression.
It is of great interest that Elovl3 is the first positively regulated Zhx2 target
and is expressed in normal adult mouse livers. The increasing levels of Zhx2 and
Elovl3 in the perinatal period matches the physiological need for proper skin and
fur development [134], thermal regulation [135], and maintenance of storage
triglyceride pools [133]. While our studies have focused on liver, future studies
should evaluate Zhx2 and Elovl3 in other tissues, particularly skin and brown
adipose tissue.
Previous mouse studies have shown that Elovl3 is expressed at higher
levels in males than in females [122]. The transcriptional basis for this genderbiased expression is not fully understood. We found that Elovl3 levels increase in
both sexes in the first month after birth, but were puzzled to find that Elovl3
mRNA levels were roughly 10-fold higher in female liver than in male liver at p28.
However, we observed a dramatic increase and decrease of Elovl3 in male and
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female liver, respectively, between p28 and p56, resulting in male-biased
expression by 2 months of age that is consistent with other reports. Since this
Elovl3 increase in males coincides with a dramatic increase in Zhx2 levels and
occurs at a time of sexual maturity, it is possible that male hepatic Elovl3
expression is regulated by growth hormone signaling. Whether Zhx2 is also
regulated by growth hormone will require further study. It should also be noted
that Elovl3 displays a circadian expression pattern in males, whereas female
mice appear to have constant, low-level Elovl3 expression [122, 139]. Zhx2 also
exhibits a circadian pattern of expression (K. Esser, Personal communication),
suggesting a possible role for Zhx2 in diurnal changes in the expression of Elovl3
and other target genes.
While Elovl3 levels are low in adult female mice, this basal Elovl3
expression is still sufficient to have physiological impact. Zadravec et al. [86]
reported that Elovl3 ablation resulted in resistance to diet-induced obesity and
was much more pronounced in females than males. The sex difference in the
magnitude of expression is similar in the other elongase family members as well.
Although the potential impact is unknown, it would be interesting to determine if
the constant elongase expression in females result in a favorable lipid pool
concentration that confers protective effects and reduces disease risks in women
more so than men.
Previously identified Zhx2 targets are disregulated in HCC. Most, but not
all studies suggest that AFP and H19 do not have functional role in HCC
progression, but there is strong data that Gpc3 can promote cancer [46, 47]. This
raises the question whether Zhx2 regulates liver tumor formation. Data from Dr.
Chunhong Ma and colleagues at Shandong University in China, with whom we
have had a longstanding collaboration, suggest that Zhx2 proteins are primarily
in the nucleus in normal hepatocytes but are localized in the cytoplasm in HCC
samples. This would suggest that Zhx2 is disregulated in HCC, and that this is
occurring at the post-translational level. Irrespective of Zhx2, we have found that
Elovl3 is repressed in mouse HCC samples. Preliminary analysis of human
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samples at Shandong University show no significant differences in Elovl3 mRNA
levels between human HCC samples and surrounding non-tumor tissues, but
further analysis is warranted.
The dramatic downregulation of Elovl3 in liver regeneration and HCC
samples in mice led us to investigate a causal role for Elovl3 in cell proliferation.
By transfections in cultured cells, our data indicate that Elovl3 can repress Huh7
growth in soft agar and in cell monolayers and can alter Hela cell cycle
progression and Cyclin expression. A functional consequence of reduced Elovl3
levels could include a diminished supply of saturated and monounsaturated
VLCFAs that would disrupt cell membrane integrity and fluidity, and the synthesis
of sphingolipids [140]. Elovl3 expression in the liver is necessary for the
generation of C20:1, C22:1, and C24:1 VLCFAs. Lipids of these categories are
generally incorporated into sphingolipids in the plasma membrane and have
been implicated in roles of signaling events, proliferation, and apoptosis [141,
142]. Future studies should explore the relationship between Elovl3 and these
lipids and how this might influence cell proliferation.

67

Figure 19. Zhx2 positively regulates Elovl3 expression in adult mouse liver.
Liver RNA from male Zhx2f/f and Zhx2∆hep littermates analyzed by qRT-PCR.
Zhx2 deletion from hepatocytes (A) results in reduction of Elovl3 expression
nearly 75% (B). *p<0.05, ***p<0.001.
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Figure 20. Elovl3 is developmentally activated in the perinatal mouse liver,
but silenced in female adult liver. Liver RNA extracted from B6C3F1 offspring
collected at developmental timepoints was analyzed by qPCR. Zhx2 expression
increases with age (A, B) and Zhx2 increases with sexual maturation in male
mice by d56. Correspondingly, Elovl3 expression increases during development
(C, D). At d56, female mice have ~20-fold Elovl3 repression while males have
~10-fold increase. Developmental expression compared to e17.5, *p<0.05,
**p<0.01, ***p<0.01.
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Figure 21. Expression of elongase genes in male liver. Liver RNA from 5week old Zhx2f/f and Zhx2∆hep littermates was analyzed by qRT-PCR for relative
elongase expression. Elovl3 and Elovl2 are the most abundantly expressed
elongases in the liver. Elovl1 has low hepatic expression and is reduced in
Zhx2∆hep mice, as is Elovl3 expression. *p<0.05.
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Figure 22. Elovl3 is repressed in a mouse model of HCC. B6C3F1 male mice
were injected with DEN (n=15) or PBS (n=5) to induce HCC tumor formation.
Samples were collected 36 weeks post-injection. Elovl3 expression was
dramatically reduced in tumors (A). Other elongases are also disregulated in
HCC (B); Elovl2 is activated and Elovl6 is repressed. *p<0.05, ****p<0.001.
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Figure 23. Elovl3 suppresses HCC cell anchorage independent growth.
Huh7 cells were transfected with either pcDNA3.1 empty vector (control) or
Elovl3 expression plasmid, plated in media-supplemented soft agar and
incubated for one week. Cell viability was measured using a luminescent DNA
binding dye. Controls were set to 100%. Elovl3 expression reduced cell growth
by 30%. *p<0.05.
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Figure 24. Elovl3 expression stalls cell in S-phase. Hela cells were cotransfected with GFP and either pcDNA3.1 empty vector (Control) or Elovl3
expression plasmid. Cells were synchronized in G1 then collected at hourly
timepoints after release. GFP positive cells were analyzed by FACS to determine
the proportion of cells in each cell cycle phase. Elovl3 and control cells are not
different in progression through G1 (A). Elovl3 expression increases the number
of cells in S-phase (B) which accounts for fewer cells in G2/Mitosis (C). This
data suggests that Elovl3 reduces cell proliferation by stalling cells in S-phase.
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Figure 25. Elovl3 expression alters expression of Cyclins. Cell RNA was
collected at hourly timepoints after release from G1 synchronization and
analyzed by qRT-PCR for expression of Cyclin D, E, A, and B. Control cells
increase expression of Cyclins D, E, and A three hours after release (A, B, C).
Expression of Cyclins is delayed and blunted in Elovl3 transfected cells. Altered
expression of Cyclins could contribute to the delay of cell progression through the
cell cycle.
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Chapter Six
Summary and Future Directions
The data reported in this dissertation characterize Zhx2 as a
transcriptional regulator of genes involved in lipid, steroid and xenobiotic
metabolism, sex-specific gene patterning, and cell cycle regulation. Zhx2 has
previously been reported to act directly on some of its targets to repress
expression (AFP, Cyclins A and E, Gpc3) [34, 35, 143]. To date, the mechanism
by which Zhx2 regulates many of its targets has not been determined. The fact
that some targets are positively regulated while others are expressed suggests
Zhx2 may part of a much larger signaling and regulatory complex.
This dissertation describes the first analysis using mice with a floxed Zhx2
allele. My studies in Zhx2∆hep mice have identified new Zhx2 targets in entirely
new areas of metabolism and cell function. Based on findings in studies with
BALB/cJ mice, we expected that Zhx2 regulated many genes in lipid and
cholesterol metabolism. I found that Zhx2 regulates ChREBP, Cpt1a, MAT1a,
and CD36. The functional parameters of these genes align with characteristics of
previously identified targets. Interestingly, Zhx2 appears to impact levels of
transcription factors HNF4α and PPARγ. HNF4α, in particular, is a major
regulator of liver gene expression. HNF4α is critical to liver function; deletion of
the gene is embryonic lethal [96, 144] and loss of expression increases cell
proliferation and HCC [145]. My finding that Zhx2 deletion in hepatocytes
reduces HNF4α expression implicates Zhx2 involvement, at least by indirect
means, of a large portion of genes and metabolic functions in the liver. To gain
better insight into the function and impact of Zhx2, ChIP-seq analysis should be
performed to identify targets with which Zhx2 has direct interaction, and RNA-seq
data will provide a better understanding of the broader effects of Zhx2 on gene
expression. Multiple HNF4α binding sites have been found in the Zhx2 promoter
(K. Schroeder, personal communications), suggesting potential cross-talk
between these factors that govern similar hepatic functions.
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Another interesting facet of Zhx2 is its role in developmental gene
expression. Zhx2 targets that we have investigated in detail in mouse
development (AFP, Cyp2a4, Elovl3) display an expression pattern from
embryonic to young adulthood that corresponds with increasing Zhx2 levels
during this timeframe. This development regulation has become a hallmark of
Zhx2 targets. In addition to HNF4α, the Zhx2 targets Lpl, Gpc3, and Cpt1a are
necessary for proper fetal development and mutations in these genes can cause
perinatal death. Since Zhx2∆hep mice could be obtained, liver-specific Zhx2
expression is not absolutely essential. However, while not included in this
dissertation, breeding Zhx2∆hep mice revealed an extremely unusual phenotype in
that some offspring were born underdeveloped and missing internal organs, and
many others dies within 24 hours of birth. Perinatal death in Zhx2∆hep mice could
be the consequence of its disregulated targets that are important for metabolism.
The early developmental abnormalities (absence of posterior half of embryos,
lack of internal organs) seen in some of the offspring are quite puzzling, and the
physical deformities were more severe than what has been characterized in other
gene deletions. These defects are not due to the lack of Zhx2 in the livers of
offspring, but are a consequence of the lack of hepatic Zhx2 in the mothers.
While we do not know the molecular basis for this phenomenon, it is possible that
the maternal hepatic Zhx2 deletion alters nutrient availability and/or ineffective
signaling molecules essential for early embryonic patterning. This raises the
question of whether maternal Zhx2 expression and proper regulation of Zhx2
targets is required for proper fetal development in humans. Additional research
into this topic is needed.
My results identifying Zhx2 as a regulator of Cyp2a4 during sexual
maturity of male mice reveals a new role for Zhx2. The dramatic increase in Zhx2
expression seen only in male mice from 4 weeks of age to 8 weeks of age
suggests Zhx2 is activated by steroid hormone signaling during sexual
maturation. Increased Zhx2 in sexually mature male mice could increase
expression of STAT5b and HNF4α, as my data indicates they are both positively
regulated by Zhx2 expression in 5 week old mice, but this needs to be further
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examined in older mice. My data provides compelling evidence that Zhx2 is an
important component of the GH-STAT5-HNF4α signaling axis that is necessary
for sex-specific gene expression in the liver. The difference in the expression of
multiple Cyp enzymes in males and females has great implications in disease
risks. In mice and in humans, males are generally at higher risk than women for
fatty liver, liver damage, and HCC . In contrast, women are at higher risk of liver
damage from alcohol use [146]; incidentally, women may have lower expression
of Cyp2e1, the enzyme that metabolizes alcohol [147, 148]. CVD is the primary
cause of death for both men and women in America, but the characteristics differ
between sexes. CVD onset is delayed in women with complications appearing
about 10 years later than the average age of men [149]. Menopause and
hormonal perturbations coincide with the timing of CVD presentation in women.
Since GWAS studies have confirmed Zhx2 as a risk factor for CVD in humans
[76, 77], it is tempting to speculate that Zhx2 may contribute to the gender
differences in disease susceptibility through its coordination of hormone signaling
and sex-specific gene patterning. Differential Cyp gene expression could
contribute to altered steroid and xenobiotic metabolism and directly impact the
development of both fatty liver and cardiovascular disease, as well as the
efficacy of therapeutic interventions for these conditions. Therefore, the
cardioprotective phenotype seen in BALB/cJ mice might be due in part to the
“feminization” of the liver caused by diminished Zhx2 and altered sex-specific
expression of Cyps and other proteins. An extension of this observation would be
to see if hepatic Zhx2 deletion causes a switch in gender-associated disease, i.e.
if female Zhx2∆hep mice have increased liver damage and HCC compared to
males. Further, I have established a role for Zhx2 in the sexual maturity of male
mice, and our lab has shown its role in gene regulation during development. As
sex hormones diminish with age, it is logical to examine the expression of Zhx2
in aging mice as well. It will be interesting to explore the role of sex hormones on
Zhx2 expression, hepatic gene regulation, and the resulting risk of both liver
damage and cardiovascular disease throughout the life cycle in mice.
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Zhx2 regulation of Elovl3 provides novel insight into the role of Zhx2 in
lipid signaling and cellular metabolism. AFP and H19 are known to be
disregulated in HCC and are clinically relevant as biomarkers, but it is not clear if
or how their increased expression is involved in tumor formation. Gpc3, another
Zhx2 target, is a cell surface proteoglycan that has been shown to influence liver
tumor formation [150]. However, my data showing a link between Zhx2, Elovl3,
and cell proliferation represents metabolism as another means by which Zhx2
might influence HCC. Elovl3 synthesizes VLCFAs which often are incorporated
into cell membranes, constitute sphingolipids, and are conductors of signaling
events.[141, 142] There is growing interest in the role of sphingolipids, and
ceramide metabolites, in regulating important cell fate processes such as growth
and proliferation, apoptosis, and autophagy, among others. Ceramides and their
analogues are being tested as therapeutics for cancers due to their role in cell
cycle arrest and inducing apoptosis [151, 152]. My data shows that Elovl3
expression contributes to cell cycle arrest, but the mechanism is unknown. It is
possible that treatment of cancerous cell lines with Elovl3 lipid products could
recapitulate the results of my study. Work is being done in our lab to isolate,
culture and transfect primary hepatocytes, which will be an ideal model to
perform these studies. Transfections with Elovl3 expression plasmids in these
cells followed by LCMS analysis could identify the ceramide or sphingolipid
compounds resulting from Elovl3 activity under normal condition. These lipids or
synthetic analogs could be used to treat cells exposed to carcinogenic toxins to
evaluate the effectiveness in regulating cell proliferation in a disease model.
Further understanding of the role of Elovl3 in cell cycle regulation could provide a
new avenue for therapeutic potential.
Zhx2 regulates genes involved diverse functions that are important for
health and normal metabolism. This makes Zhx2 a potential target for
manipulation and mutation in disease. Many of the processes that are
disregulated in Zhx2∆hep mice parallel activities attributed to the mTOR pathway.
mTOR complex 1 (mTORC1) receives signals from insulin and growth factors
and senses nutrient status through AMP/ATP ratio and amino acid abundance
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[153]. mTORC1 activation results in new gene transcription, increased de novo
lipogenesis, increased cell growth and proliferation, and inhibition of autophagy.
mTOR is regulated by feedback inhibition from diminished nutrient availability
(AMPK), amino acid deprivation, and glucocorticoid signals. When disregulated,
mTOR activity proceeds without inhibition and can lead to diseases, including
cardiovascular disease and cancer [153, 154]. Zhx2 is integral in conducting
signals from GH and effecting gene expression regulation in response. My data
suggests that disregulated Zhx2 function disengages nutrient sensing of lipids in
hepatocytes resulting in excess fat accumulation, a condition that is exacerbated
by faulty lipid export. In HFD conditions, the fatty liver environment in Zhx2∆hep
mice provides abundant lipid substrate required by cancer cells for membranes
and signaling molecule in rapidly dividing cells [155]. The apparent overlap of
mTOR activity and Zhx2 regulation of lipid synthesis, growth signaling, cell
proliferation, and associations with CVD, cancer, and multiple other disorders
suggests Zhx2 could be a part of or affected by mTOR pathways. Future studies
into a relationship between mTOR and Zhx2 disregulation in lipid metabolism and
cell growth could provide new insight into key events in early stages of CVD and
liver disease, including HCC.
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